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ABSTRACT 
Cardiovascular diseases (CVD) are a major cause of death and disability in Western 
countries and a growing health problem in the developing world. The genetic 
component of both coronary heart disease (CHD) and ischemic stroke events has 
been established in twin studies, and the traits predisposing to CVD, such as 
hypertension, dyslipidemias, obesity, diabetes, and smoking behavior, are all partly 
hereditary.  
This thesis aimed to clarify the genetic background of CVD at a population level 
using large Nordic population cohorts and a candidate gene approach. The first 
study concentrated on the allelic diversity of the thrombomodulin (THBD) gene in 
two Finnish cohorts, FINRISK-92 and FINRISK-97. The results from this study 
implied that THBD variants do not substantially contribute to CVD risk.  
In the second study, three other candidate genes were added to the analyses. The 
study investigated the epistatic effects of coagulation factor V (F5), intercellular 
adhesion molecuce -1 (ICAM1), protein C (PROC), and THBD in the same 
FINRISK cohorts. The results were encouraging; we were able to identify several 
single SNPs and SNP combinations associating with CVD and mortality. 
Interestingly, THBD variants appeared in the associating SNP combinations despite 
the negative results from Study I, suggesting that THBD contributes to CVD through 
gene-gene interactions. 
In the third study, upstream transcription factor -1 (USF1) was analyzed in a cohort 
of Swedish men. USF1 was associated with metabolic syndrome, characterized by 
accumulation of different CVD risk factors. A putative protective and a putative risk 
variant were identified. A direct association with CVD was not observed. The 
longitudinal nature of the study also clarified the effect of USF1 variants on CVD 
risk factors followed in four examinations throughout adulthood. 
The three studies provided valuable information on the study of complex traits, 
highlighting the use of large study samples, the importance of replication, and the 
full coverage of the major allelic variants of the target genes to assure reliable 
findings.  
Keywords: Cardiovascular diseases, genetic association analysis, candidate gene 
approach, F5, ICAM1, PROC, THBD, USF1
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TIIVISTELMÄ 
Sydän- ja verisuonisairaudet ovat länsimaiden johtava kuolinsyy, ja kasvava 
ongelma kehitysmaissa. Koronaaritaudin ja iskeemisen aivohalvauksen 
perinnöllisyys on osoitettu kaksostutkimuksissa. Lisäksi useat tautiryhmän 
riskitekijöistä, kuten kohonnut verenpaine, rasva-aineenvaihdunnan häiriöt, 
lihavuus, sokeritauti ja nikotiiniriippuvuus ovat osittain perinnöllisiä. 
Tämän väitöskirjatyön tavoitteena oli selventää viiden tromboosi- ja 
lipidiaineenvaihduntaan osallistuvan geenin osuutta sydän- ja verisuonitautien 
riskitekijöinä. Aihetta lähestyttiin väestötasolla, kookkaita pohjoismaisia 
väestöotoksia ja ehdokasgeeniasetelmaa hyödyntäen. Kirjan ensimmäinen osatyö 
keskittyi trombomoduliinigeeniin (THBD), jota tutkittiin kahdessa suuressa 
suomalaisessa väestöotoksessa (FINRISKI-92 ja FINRISKI-97). Yhteyttä THBD-
geenin ja sydän- ja verisuonitautien välillä ei kuitenkaan havaittu. 
Toinen osatyö käsitteli neljän geenin yhteisvaikutuksia sydän- ja verisuonitautien 
taustalla. Hyytymistekijä V, intersellulaarinen adheesiomolekyyli -1 ja proteiini C 
genotyypattiin samoissa FINRISKI-otoksissa ja analysoitiin yhdessä 
trombomoduliinin kanssa. Tulokset olivat rohkaisevia: useat yksittäiset polymorfiat 
ja polymorfiaparit lisäsivät tautiriskiä, ja tulokset olivat yhteneviä molemmissa 
väestökohorteissa. Ensimmäisen osatyön negatiivisista tuloksista huolimatta myös 
THBD-variantit lisäsivät tautiriskiä. Siten THBD saattaa vaikuttaa sydän- ja 
verisuonitauteihin geenien välisen interaktion kautta.  
Kolmas osatyö keskittyi lipidigeeni upstream transcription factor -1:n (USF1) 
analyyseihin ruotsalaisessa mieskohortissa. Kardiovaskulaaritapahtumien lisäksi 
tutkittiin metabolista syndroomaa. USF1:n geenivariantit vaikuttivat metaboliseen 
syndroomaan sekä suojaavasti että riskiä lisäten. Suoraa yhteyttä sydän- tai 
aivotapahtumiin ei havaittu.  
Yhdessä nämä kolme osatyötä tuottivat arvokasta tietoa monitekijäisten tautien 
tutkimuksesta, korostaen suurten väestöotosten merkitystä ja positiivisten löydösten 
toistamista toisessa aineistossa, sekä kohdegeenien yleisten varianttien kunnollista 
kattamista luotettavien tutkimustulosten takaamiseksi. 
Avainsanat: Sydän- ja verisuonitaudit, geneettinen assosiaatioanalyysi, 
ehdokasgeeniasetelma, F5, ICAM1, PROC, THBD, USF1   
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ABBREVIATIONS 
ABCA1  ATP-binding cassette -1, subtype A gene 
AD  Alzheimer’s disease 
APC  Activated protein C  
ApoE  Apolipoprotein E  
APOE  Apolipoprotein E gene 
ATPIII National Cholesterol Education Program’s Adult 
treatment panel III  
BMI  Body mass index 
CHD  Coronary heart disease 
chr  Chromosome 
Cm  Chylomicrons 
CNV  Copy number variation 
CVD  Cardiovascular diseases 
DNA  Deoxyribonucleid acid 
EGIR European Group for the Study of Metabolic 
Syndrome  
F2  Prothrombin (Coagulation factor II) gene 
F5  Coagulation factor V gene 
F7  Soluble factor VII 
F7  Coagulation factor VII gene 
FXIII  Coagulation factor XIII gene 
FCHL  Familial combined hyperlipidemia 
FDR  False discovery rate 
GLM    General linear model 
GWAS  Genome-wide association study 
HDL  High density lipoprotein cholesterol 
HR  Hazard ratio 
ICD  International classification for diseases 
ICAM1  Intercellular adhesion molecule -1 gene 
IDF  International Diabetes Federation 
IDL  Intermediate density lipoprotein cholesterol 
kb  Kilobase 
LD  Linkage disequilibrium 
LDL  Low density lipoprotein cholesterol 
Lp(a)                       Lipoprotein a 
LPL  Lipoprotein lipase 
MetS  Metabolic syndrome 
MI  Myocardial infarction 
MTHFR  5,10- methylenetetrahydrofolate reductase gene 
n  Number 
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NO  Nitric oxide 
PAI1  Plasminogen activator inhibitor -1  
PAI1  Plasminogen activator inhibitor -1 gene 
PLAT  Tissue plasminogen activator  
PLAT  Tissue plasminogen activator gene 
PROC  Protein C gene 
sICAM1  Soluble intercellular adhesion molecule -1 
SMC  Smooth muscle cell 
SNP  Single nucleotide polymorphism 
sTM  Soluble thrombomodulin 
T2DM  Type 2 diabetes mellitus 
TAFI  Thrombin activatable fibrinolysis inhibitor gene 
TC  Total cholesterol 
TF  Tissue factor 
TG  Triglycerides 
THBD  Thrombomodulin gene 
ULSAM  Uppsala Longitudinal Study of Adult Men 
USF1  Upstream transcription factor -1 gene 
VLDL  Very low density lipoprotein cholesterol 
WHO  World Health Organization 
 
 
 
Gene names are italicized in the text.  
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INTRODUCTION 
Coronary heart disease (CHD) is currently the leading cause of death and disability 
in Western countries and is likely to become the leading cause of death worldwide 
by 2020 (Murray and Lopez 1997). The World Health Organization estimated that 
nearly 8 million people worldwide died of CHD in 2005 (www.who.int). In the 
United States alone, CHD affects 15 million people (Rosamond et al. 2007), and 
300 000 individuals each year suffer sudden cardiac death, 80% of which of 
atherosclerotic origin (Wang 2005). Further, atherosclerosis, the underlying cause 
for cardiovascular diseases (CVD), is estimated to account for over 50% of all 
deaths in the United States (Lusis 2000).  
During the last three decades, incidence of both first and recurrent coronary events 
has, however, declined steeply in Western countries due to major efforts in disease 
prevention and care. In Finland, mortality from recurrent coronary events dropped 
approximately 10% per year in 1983-1992 (Salomaa et al. 2003). Especially out-of-
hospital mortality decreased during this period (Salomaa et al. 2003). Nevertheless, 
in 2004 CHD caused over 77 000 hospitalizations and about 12 000 deaths in 
Finland, and approximately 14 000 first myocardial infarctions (MI) were detected 
(www.stakes.fi). 
Stroke morbidity imposes a substantial health burden, with mortality, lifelong 
handicap, and loss of “quality years” of life, causing permanent disability for up to 
30% of those with non-fatal events (Goldstein et al. 2006). Stroke events also 
increase the risk for dementia later in life (Ivan et al. 2004). The lifetime risk for 
stroke was approximately 13% in middle-aged Americans (Seshadri et al. 2006). In 
Finland, about 14 000 stroke events take place annually (www.stakes.fi). In the past 
decades especially stroke mortality has decreased significantly (Tuomilehto et al. 
1996, Sivenius et al. 2004, Pajunen et al. 2005 a). 
This study investigated the role of genetic risk factors in CVD, concentrating on five 
candidate genes. The focus was at the population level where data on well-
established genetic CVD risk variants are scarce. The completion of the Human 
Genome Project launched projects like HapMap, providing detailed information on 
haplotype structures across the genome, greatly facilitating the study of complex 
traits. In addition, technological achievements in the field have provided the means 
to unravel the genetic basis of common diseases. The following literature review 
provides an insight to cardiovascular diseases and their genetic background, and 
explores ways of discovering genes underlying CVD and other complex traits. 
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REVIEW OF THE LITERATURE 
1. ATHEROSCLEROSIS    
Atherosclerosis is a progressive disease of the major arteries, giving rise to 
cardiovascular outcomes, such as coronary heart disease and ischemic stroke. Other 
atherosclerotic manifestations include atherosclerosis of the lower limbs and 
ruptures of large vessels such as the aorta. Atherosclerosis is a dynamic disease 
process involving lipid accumulation, disturbed endothelial function, inflammatory 
response with recruitment of inflammatory cells and cytokine secretion, smooth 
muscle cell (SMC) proliferation in the intima, and ulceration and thrombosis of the 
plaque (Ross 1999, Lusis 2000).  
The arterial wall consists of three layers, the intima, media and adventitia. The 
intima, the inner layer, is lined with endothelium: a single layer of flat epithelial 
cells and a base membrane of connective tissue and smooth muscle cells. The media 
is the muscle layer of the artery, outlined with connective tissue of the adventitia. 
The normally very thin intima is thickened when affected by atherosclerosis. Based 
on histological changes in the intima, the American Heart Association has suggested 
a six-stage grading for atherosclerotic lesions (Table 1) (Stary et al. 1994, Stary et 
al. 1995). Type I lesions contain lipid-laden macrophages, foam cells. Type II 
lesions are characterized by several layers of foam cells. Type III lesions contain 
additional extracellular cholesterol, while type IV lesions have a clear lipid core. 
Type V lesions have a fibrous cap of fibromuscular fibers. Type VI lesions contain 
ulcerations, hematoma, or thrombosis on the plaque surface. Type I lesions represent 
very initial atherosclerosis typically seen in children. Fatty streaks belong to type II 
lesions. Type III lesions, common in young adults, lay between early and advanced 
atherosclerosis, presenting initial intimal thickening. Only advanced lesions (types 
IV-VI) cause clinical symptoms. 
Table 1. Histological grading of atherosclerotic lesions according to the American 
Heart Association (modified from Stary et al. 1994, Stary et al. 1995). 
Lesion type                       Histological characteristics 
Early lesions  Type I Foam cells at lesion site 
 Type II Several separate foam cell layers present 
Intermediate lesions Type III Extracellular cholesterol droplets 
Advanced lesions Type IV Distinctive lipid core in the lesion  
 Type V Fibrous cap present, calcification may be seen (Type Vb) 
 Type VI           Surface ulceration, hematoma, or thrombosis 
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1.1. A short overview of lipid metabolism 
Lipid particles are transported in plasma in water-soluble lipoproteins (Gotto et al. 
1986).  The core of lipoproteins consists of triglycerides (TGs) and cholesterol 
esters, surrounded by phospholipids, apolipoproteins, and free cholesterol. 
Lipoproteins are divided into five classes by density: chylomicrons (Cms), very low 
density lipoproteins (VLDLs), intermediate density lipoproteins (IDLs), low density 
lipoproteins (LDLs), and high density lipoproteins (HDLs) (Gotto et al. 1986). Cms 
form in the intestine from dietary lipids and bile, and are cleared from the circulation 
by lipoprotein lipase (LPL). LPL facilitates the breadown of TG of Cm, giving rise 
to free fatty acids and Cm remnants. If not stored in adipose tissue as free fatty 
acids, TG can be utilized in the liver to form VLDL. VLDL is secreted from the 
liver into the circulation, where it is modified by LPL and hepatic lipase to form IDL 
and further LDL. LDL transports cholesterol to peripheral tissues via LDL receptors. 
HDL is a key player in reverse cholesterol transport, returning cholesterol from 
tissues to liver to be exreted into bile. Cholesterol ester transfer protein transfers 
cholesterol esters from HDL to IDL and LDL. When functioning excessively, this 
cycle contributes to formation of highly atherogenic, small, dense LDLs. Other 
HDL-modifying enzymes include lecithin:cholesterol acyl transferase and 
paraoxonase -1.  
Apolipoproteins act as stabilazers in soluble lipoproteins, as enzymatic cofactors, 
and as ligands for lipoprotein receptors. Apolipoproteins A-1 (ApoA-1) and A2 are 
the main apolipoproteins in HDL, and apolipoprotein B (ApoB) is the major 
component of other apolipoproteins. Apolipoprotein E (ApoE) serves as a ligand for 
LDL receptor and is needed in formation of VLDL and Cms (Eichner 2002). Lipid 
metabolism is illustrated in Figure 1. 
 
1.2. Early atherosclerotic lesions 
Atherosclerotic changes begin with lipid accumulation in the vessel wall. Early 
lesions are visible in humans already in the first decade of life (Lusis 2000). The 
process usually begins in the aorta, proceeding to the coronary arteries during the 
second decade and to the cerebral arteries in the third or fourth decade (Lusis 2000). 
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Figure 1. Overview of lipid metabolism.  
ABCA1: ATP-binding cassette -1, subtype A; CETP: Cholesterol ester transfer protein; Cm: Chylomicrons; 
HDL: High density lipoprotein cholesterol; HL: Hepatic lipase; IDL: Intermediate density lipoprotein 
cholesterol; LCAT: Lecithin:cholesterol acyl transferase; LDL: Low density lipoprotein cholesterol; LPL: 
Lipoprotein lipase; TG: Triglycerides. 
 
Early atherosclerotic lesions, called fatty streaks, contain mainly foam cells; 
macrophages laden with LDL cholesterol. Lesion formation begins when lipid 
particles, together with inflammatory monocytes and T lymphocytes, accumulate at 
the site (Ross and Glomset 1976 a, Ross and Glomset 1976 b, Ross 1999). 
Monocytes then migrate into the subendothelial space and differentiate into 
macrophages, which express scavenger receptors necessary for LDL uptake 
(Mahmoudi et al. 2007). Before LDL can be taken up by the macrophages, it has 
must be modified by oxidation and other ways including lipolysis, proteolysis, 
glycation (in diabetes), or different forms of aggregation with other cells or 
complexes (Ross 1999, Lusis 2000). Accumulation of oxidized LDL into the artery 
wall triggers inflammatory response with the recruitment of monocytes and 
lymphocytes at the lesion site (Ross 1999). LDL accumulation can also stimulate 
these inflammatory cells, being thus the major initiating event in atherogenesis.  
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1.3. Endothelial dysfunction 
The endothelium is a dynamic organ regulating vasodilatation and vasoconstriction, 
local inflammatory response, and thrombogenic-thrombolytic balance at the vessel 
wall. The endothelium also controls fibrinolysis and SMC stimulation, inhibition, 
proliferation, and differentiation (Kinlay et al. 2001, Mahmoudi et al. 2007). Healthy 
endothelium is a smooth, nonthrombogenic permeability barrier between the 
circulation and arterial wall (Stary et al. 1992).   
Endothelial dysfunction is a highly atherogenic process characterized by an imbalance 
between vasoconstriction and vasodilatation, and increased vessel wall permeability. 
Several CVD risk factors impair the normal functions of endothelial cells. 
Dyslipidemias, vasoconstrictor hormones involved in hypertension, diabetes-associated 
glycoxidation, proinflammatory cytokines, smoking-derived free radicals, shear stress, 
infectious agents like herpesviruses and Chlamydia pneumoniae, and genetic variations 
may injure the endothelial cells (Libby et al. 2005, Mahmoudi et al. 2007).  
A key player in vasodilatation, in addition to prostacyclin and bradykinin, is nitric 
oxide (NO). Lipids, especially LDL, together with local oxidative stress, reduce NO 
amount and availability, impairing vasodilatation.  Small invaginations in the 
endothelial cell surface, caveolae, contain caveolin –1, which inactivates nitric oxide 
synthase. LDL stimulates caveolin –1 synthesis and increases nitric oxide synthase 
inactivation, enhancing vasoconstriction (Kinlay et al. 2001). Lipids also promote 
inflammation by activation of inflammatory pathways. Inflammatory response leads 
to accumulation of monocytes and macrophages at the lesion site and their 
subsequent adhesion and transmigration into the intima. HMG-CoA reductase 
inhibitors, LDL-lowering statins, in turn, reduce caveolin –1 expression (Kinlay et 
al. 2001). The endothelium responds to shear stress first by increasing NO and 
vasodilatation, but in time by vasoconstriction (Gimbrone et al. 2000). 
 
1.4. Inflammation 
Recent insights from the molecular level highlight atherosclerosis as an 
inflammatory process (Ross 1999, Lusis 2000). Inflammation is present at all stages 
of atherosclerosis, from early fatty streaks to the most complex lesions, contributing 
importantly to lesion growth. The key inflammatory cells involved in atherosclerosis 
are monocyte-derived macrophages and T lymphocytes, both which gather at the 
lesion site due to local changes caused by endothelial dysfunction, enter the vessel 
wall, and stimulate series of events leading to lesion enlargement and destabilization 
(Soll et al. 2006). Early atherogenic lesions are, in fact, pure inflammatory lesions, 
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consisting of inflammatory cells, mainly monocyte-derived macrophages and T 
lymphocytes.  
Vascular cell adhesion molecules have a central role in atherogenesis (Ridker 2001). 
Selectins E, L, and P are involved in the leukocyte capture and rolling on the 
endothelial surface. L selectin is expressed in leukocytes, selectin P in platelets, and 
selectins E and P in endothelial cells when inflammation prevails (Galkina and Ley 
2007). Intercellular cell adhesion molecule -1 (ICAM1) and vascular cell adhesion 
molecule -1 (VCAM1) contribute to leukocyte adhesion. In endothelial dysfunction, 
endothelial cells upregulate the expression of monocyte- and T-cell-binding cell 
surface receptors and cell adhesion molecules ICAM1 and VCAM1 (Mahmoudi et 
al. 2007). ICAM1 and VCAM1 are also expressed in the SMCs in atherosclerotic 
plaques (Braun et al. 1999). Connexins are involved in the transmigration of 
inflammatory cells (Galkina and Ley 2007).   
After migration from the blood stream to the arterial intima, the inflammatory cells 
activate SMCs to migrate from the media to the intima, proliferate, and secrete 
extracellular matrix (Libby et al. 2005). The matrix contains matrix 
metalloproteinases, which in turn modulate numerous changes in vascular cells 
(Libby et al. 2005). In the intima, the macrophages form foam cells by scavenging 
modified LDL particles and maintain chemotaxis by producing cytokines and 
proteolytic enzymes. The macrophages themselves induce production of tissue 
factor (TF), cytokines, and matrix metalloproteinases (Soll et al. 2006). In addition, 
T lymphocytes secrete cytokines when activated by antigens such as oxidized LDL. 
Thus, macrophages and T lymphocytes maintain the inflammation process at the 
lesion site.  
Animal studies have provided important insights to the role of inflammation in 
atherosclerosis. Apolipoprotein E -deficient (apoE -/-) mice express substantially 
high cholesterol levels and develop extensive atherosclerosis (Piedrahita et al. 1992, 
Plump et al. 1992). Zhou and associates (1996) addressed the inflammatory process 
in apoE -/- mice and observed that the atherosclerotic lesions in the mice were laden 
with inflammatory T cells. Further, cross-breeding apoE -/- mice with severe 
combined immunodeficiency mice lacking both B and T cells significantly reduced 
fatty streak development (Zhou et al. 2000). Gene therapy targeted against 
chemoatractive functions of monocytes or macrophages reduced atherosclerosis in 
apoE -/- mice (Borin et al. 1998, Inoue et al. 2002). Moreover, crossing apoE -/- 
mice with mice lacking functional macrophages resulted in diminished lesions 
(Smith et al. 1995). Mice deficient for selectins have less extensive atherosclerosis 
under fatty diet (Galkina and Ley 2007). 
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1.5. Thrombosis 
Vascular thrombosis can be divided into two distinct groups differing in the site of 
occurrence and thrombus composition. The issue has been reviewed by Reitsma 
(2004): Arterial thrombosis is an end-stage disease of atherosclerotic medium size 
and large arteries, typically seen in areas with fast blood flow. Arterial thrombi 
consist primarily of platelets. Venous thrombosis occurs most often in stasis areas of 
blood flow, mainly in deep, large veins of the lower extremities and in pulmonary 
arteries. Instead of platelets, the main components in venous thrombi are fibrin and 
red blood cells. 
Thrombosis is a key feature in advanced atherosclerotic lesions (Stary et al. 1995). 
Plaque ulceration and rupture expose the tissue underlying the endothelium, 
initiating a series of blood clotting events, leading to thrombus formation on the 
lesion surface (Spronk et al. 2004). Thrombotic lesions grow in size, restricting the 
flow of blood and oxygen in vessel lumen. Thrombotic lesions are also prone to 
rupture, subsequently causing occlusion downstream of the lesion (Libby 2002, 
Libby et al. 2005).   
 
1.5.1. Blood clotting  
The clotting pathway is a cascade of enzymatic and physical reactions, ultimately 
leading to blood coagulation. Both intrinsic and extrinsic factors can activate the 
cascade. The intrinsic pathway activates when endothelial damage exposes the 
underlying tissue; factor (F) XII turns into its activated form FXIIa, activating factor 
XI. FXIa in turn activates FIX, and FIXa in combination with FVIII activate FX. 
FXa, together with FV, phospholipid, and calcium, forms a prothrombinase 
complex, leading to formation of thrombin from prothrombin. Subsequently, fibrin 
is formed from fibrinogen. Fibrin monomers compose a network where red and 
white blood cells adhere at the coagulation site. Activation of FXIII into FXIIIa 
stabilizes the fibrin in the thrombus. The extrinsic pathway activates in the presence 
of TF. The TF – FVII complex activates FX, joining to the intrinsic pathway at this 
point. Both pathways are illustrated in Figure 2. (Cecil 2004.) 
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Figure 2. The clotting pathway is a cascade of enzymatic and physical reactions, 
leading to formation of a red thrombus (modified from Cecil 2004). 
APC: Activated protein C; Fx: Coagulation factor (inactive); Fxa: Activated coagulation factor; PAI1: 
Plasminogen activator inhibitor -1; PLAT: Tissue plasminogen activator; PROC: Protein C; TF: Tissue factor; 
THBD: Thrombomodulin. 
 
Natural anticoagulants dissolve unnecessary thrombi. Plasminogen has both 
fibrinolytic and anticoagulant functions. Tissue plasminogen activator (PLAT) turns 
plasminogen into plasmin, which dissolves both fibrinogen and fibrin. The 
dissolution products further downregulate fibrin formation. Plasmin also has effects 
on coagulation factors V and VIII. Plasminogen activator inhibitor -1 (PAI1) inhibits 
the actions of PLAT. Thrombin stimulates anticoagulation by binding to 
thrombomodulin (THBD), which transforms protein C (PROC) into its activated 
form (APC). This further inhibits factors FV and FVIII. (Cecil 2004.) 
 
1.5.2. Thrombosis and atherosclerosis 
Over time, atherogenesis proceeds from early fatty streaks to more complex lesions. 
Traditional views see lesion growth as an accumulation of SMCs in plaque. SMCs 
secrete extracellular matrix, contributing to lesion size. The increasingly large lesion 
protrudes into the lumen of the artery, finally rupturing as an occlusive thrombus 
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(Libby 2002). Thrombosis is characteristic for disease conversion from stable into 
acute phase (Stary et al. 1995).  
More recent views on thrombosis challenge traditional ones by introducing a concept 
of discontinuous lesion growth, where lesion size increases due to sudden 
microenvironmental changes such as thrombosis (Davies 1996). Three main types of 
physical disruption can occur at the lesion: superficial erosion, disruption of 
microvessels, and rupture of the lesion’s fibrous cap (Libby 2002, Libby et al. 2005). 
In superficial erosion, subendothelial collagen is revealed due to endothelial 
desquamation, leading to platelet activation and adhesion. On the other hand, an 
atherogenic lesion produces a fragile neovasculature, prone to rupture, leading to 
thrombosis in situ, thrombin generation, and platelet activation. The third type of 
disruption is the most common; rupture of the lesion’s fibrous cap brings coagulation 
factors in contact with tissue factor, promoting thrombosis. TF, triggering the intrinsic 
coagulation pathway, is a prominent component of atherosclerotic lesions, present in 
the macrophages infiltrating plaques (Spronk et al. 2004). 
Thrombosis is also related to conditions predisposing to atherosclerotic outcomes. 
Normal insulin actions may reduce thrombus formation (Trovati et al. 1995). Insulin 
resistance, linked to obesity, may thus increase thrombogeneity through reduced 
platelet inhibition (Westerbacka et al. 2002). Obesity likely contributes to increased 
thrombogeneity also through other mechanisms, as reviewed by Darvall et al. 
(2007). Adipose tissue secretes numerous thrombosis-related substances such as 
adiponectin, leptin, PAI1, and TF. The secreted cytokines interleukin 6 and tumor 
necrosis factor - demonstrate obesity as an inflammatory state. Obesity, further, is 
related to oxidative stress and endothelial dysfunction, which again increase 
thrombotic activities.  
Endothelial dysfunction, inflammation, and thrombosis tightly intertwine with each 
other in atherogenesis. Thrombophilias contribute to severe inflammatory conditions 
such as sepsis (Hofstra et al. 2007). Thrombomodulin - Protein C pathway may 
promote inflammation independently of their coagulation function (Scaldaferri et al. 
2007). CVD risk factors are related to all of these conditions. Obesity, for example, 
contributes to dyslipidemias, inflammation, and thrombogenesis (Darvall et al. 2007), 
and smoking increases endothelial dysfunction (Libby et al. 2005, Mahmoudi et al. 
2007) and thrombosis (Miller et al. 1998, Fernandez et al. 2002, Pomp et al. 2007).  
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2. CARDIOVASCULAR DISEASES 
The major clinical manifestations of atherosclerosis are coronary heart disease 
(CHD), stroke, and peripheral artery disease. Here we concentrate on the two 
former, used as endpoints in the genetic studies. 
 
2.1. Coronary heart disease  
The heart is typically supplied with three main coronary arteries. The right and left 
coronary arteries arise from the ascending aorta. After a short main trunk in the left 
coronary groove between the atrium and the ventricle, the left coronary artery 
branches into two: The left circumflex branch follows the coronary groove to the 
posterior surface of the heart, and the left anterior descending (interventricular) 
branch runs towards the apex of the heart between the ventricles. Typically, the 
descending branch is larger and supplies both ventricles and the interventricular 
septum, including the atrioventricular bundle (Moore 1991). The smaller circumflex 
branch supplies the left atrium and left ventricle from the posterior side (Moore 
1991). The right coronary artery, running along the right coronary groove, typically 
feeds the right atrium, right ventricle, and atrioventricular and sinuatrial nodes 
(Moore 1991). Figure 3 illustrates the typical location of the coronary arteries.  
 
Figure 3. The heart and typical locations of the three main coronary arteries 
(modified from Netter 1989).  
 
 
 
 
 
 
 
 
 
1: Right coronary artery; 2: Left descending (interventricular) coronary artery; 3: Left circumflex coronary 
artery; 4: Aorta; 5: Left pulmonary artery; 6: Superior vena cava; 7: Left pulmonary veins; 8: Left main 
bronchus; 9: Left artrium; 10: Left ventricle; 11: Right ventricle; 12: Right atrium. 
 20 
Coronary heart disease typically manifests as chest pain, although the disease can 
also be practically symptomless. Angina pectoris refers to a pain symptom 
experienced in the chest area, possibly radiating to the neck, left shoulder, left arm, 
jaw, teeth, right arm, or epigastric region. Pain may be experienced as tightness, 
squeezing, constriction, burning pain, or dull discomfort. Stable angina is diagnosed 
with recognition of the typical symptoms. Physical effort may trigger angina, and 
the symptom is relieved by rest. Unstable angina refers to situations where the 
patient has new-onset or worsening angina, or the symptom occurs in rest. 
Atherosclerotic narrowing of one or more coronary arteries is the most common 
cause for angina. Some other ischemic causes for chest pain include coronary 
spasms, dissections, reduced oxygen supply, or increased oxygen demand. Chest 
pain may also occur due to infection or of noncardiac origin. (Cecil 2004.) 
Myocardial ischemia refers to imbalance between oxygen demand and supply in the 
myocardium. Acute coronary syndrome points to myocardial ischemia, ranging from 
unstable angina to myocardial infarction (MI) with no ST-segment elevations in 
electrocardiogram, characterized by elevation of the markers of myocardial injury 
(troponins or cardiac isoenzymes). A nonocclusive thrombus in a coronary artery is 
the most common cause for acute coronay syndrome. In MI with ST-segment 
elevation, blood flow to the myocardium is completely blocked. Coronary emboli or 
thrombosis, vasculitis, vasospasm, or trauma in the coronaries are non-atherogenic 
causes for MI (Cecil 2004.)  
Traditionally atherosclerotic narrowing of the vessels was thought to results from 
protrusion of advanced plaques into the arterial lumen. It is now understood that the 
vasculature adapts to the proceeding atherosclerosis with remodeling the blood flow 
(Korshunov et al. 2007), and substantial atherosclerosis can exists even in the 
absence of protruding plaques. These silent lesions grow outward rather than 
inward, and do not cause any clinical symptoms – before sudden changes in the 
lesion, such as thrombosis, give rise to unstable plaques (Libby et al. 2005). 
Distribution of atherosclerotic lesions in the arteries is not uniform. Flow conditions 
in the vasculature, namely shear stress, affect lesion development. The lesions are 
often seen to develop at sites where low shear stress prevails, i.e. at branch points 
and downstream of stenoses (Gimbrone et al. 2000, Stone et al. 2003). The most 
common sites of coronary occlusions are the anterior interventricular branch of the 
left coronary artery, the right coronary artery, and the circumflex branch of the left 
coronary artery (Cecil 2004).  
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2.2. Ischemic stroke 
The brain is supplied by two internal carotid arteries and two vertebral arteries 
(Figure 4). Together these arteries form an anastomosis ring at the base of the brain, 
known as the circle of Willis. The circle contains five arteries (Figure 4): posterior 
cerebral, posterior communicating, internal carotid, anterior cerebral, and anterior 
communicating arteries (Moore 1991).  
Stroke is defined as acute-onset focal loss of cerebral function. Symptoms from a stroke 
event vary, but persist for 24 hours or more, whereas similar symptoms lasting less than 
24 hours refer to transient ischemic attack. Strokes can arise due to ischemic events, 
intracerebral bleeding, or subarachnoidal hemorrhages. (Cecil 2004.) 
Of all stroke events, approximately 80% are of ischemic origin (Humpries and 
Morgan 2004). Atherosclerosis of the carotid arteries accounts for over 30% of the 
ischemic strokes (Sandercock et al. 1989). Other causes for ischemic stroke events 
are cardiogenic embolisms and atherosclerosis of the small arteries. The diagnosis of 
stroke events is based on persisting clinical symptoms and radiological imaging. 
 
Figure 4. The carotid arteries and the circle of Willis. (Modified from Netter 1989.) 
 
 
 
 
 
 
 
 
 
1: Aorta; 2: Brachiocephalic trunk; 3: Common carotid artery; 4: Internal carotid artery; 5: External carotid artery; 
6: Vertebral artery; 7: Subclavian artery; 8: Basilar artery; 9: Posterior cerebral artery; 10: Posterior 
communicating artery; 11: Middle cerebral artery; 12: Anterior cerebral artery; 13: Anterior communicating artery. 
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2.3. Cardiovascular risk factors 
CVD events rarely occur in individuals who are unexposed to risk factors. 
Greenland and coworkers (2003) observed that up to 90% of the affected persons 
had one or more risk factor. According to Lloyd-Jones et al. (2006 a), individuals 
free of the risk factor burden at the age of 50 years had a significantly lower lifetime 
risk for cardiovascular manifestations than those with two or more risk factors. 
Traditional cardiovascular risk factors comprise advanced age, male gender, 
smoking, hypertension, elevated total cholesterol (TC) and LDL cholesterol, low 
HDL cholesterol, obesity, and family history of CVD (Fruchart et al. 2004).  Newer 
risk factors for CVD include disturbances of glucose metabolism, and hemostatic 
factors and inflammatory markers (Fruchart et al. 2004).  Table 2 lists the major risk 
CVD factors.  
Table 2. Factors increasing the risk for cardiovascular events.  
FACTORS AFFECTING THE RISK OF CARDIOVASCULAR DISEASES 
Advanced age 
Male gender 
Smoking 
Hypertension 
Low socioeconomic status 
Physical inactivity 
Dyslipidemias 
Obesity 
Diabetes 
Molecular markers 
Family history 
 
Aging is a major risk factor for both CHD and stroke events. The burden of the 
CVD risk factors tends to increase by age: Advanced age relates to dyslipidemias 
(Aromaa 2002), obesity (Rahkonen et al. 1998), and hypertension (Aromaa 1981). 
The proinflammatory state accompanied with aging may also contribute to the 
development of atherosclerosis (Vasto et al. 2007). Stroke risk increases 
significantly after 55 years (Goldstein et al. 2006).  
Male gender is a significant risk factor for CHD. Over 90 000 CHD events, of which 
42 000 fatal, were recorded among men, compared with 36 000 CHD events and 
15 000 fatal events among women in the Finnish Hospital Discharge Register and 
Causes of Death Register during 1991-2001 (Pajunen et al. 2004). Jousilahti et al. 
(1999) reported a three-fold CHD risk for men compared with women. According to 
the FINMONICA register, men, compared with women, were also at 1.7 times 
increased risk for recurrent coronary event (Schreiner et al. 2001). Women, 
however, tend to fare less well after CHD events worse than men in long-term, 
possibly due to their older age at disease onset, diabetes, and other factors (Schreiner 
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et al. 2001). Men also have higher risk for stroke events (Brown et al. 1996, Sacco et 
al. 1998), except among the young and the old (<44 years or >85 years, Sacco et al. 
1998). Stroke events were slightly more common among women than men in 
Finland during 1991-2001 (Pajunen et al. 2005 a).  
Smoking approximately doubles the risk for MI (Prescott et al. 1998).  Heavy 
smokers are reported to hold a double risk for stroke compared to light smokers 
(Wolf et al. 1988). The stroke risk decreased to level of non-smokers within 5 years 
from cessation of smoking (Wolf et al. 1988). On the other hand, smoking also 
decreases life expectancy, and as the risk for cardiovascular events increases with 
age, smoking may actually decrease the probability of CVD and shorten the duration 
of the disease (Mamun et al. 2004).  
Hypertension is the most important modifiable risk factor for stroke (Goldstein et al. 
2006). Hypertension contributes to CHD and stroke risk in a dose-like manner 
(MacMahon et al. 1990), increasing the risk of cardiovascular outcomes 2- 3 -fold 
(Kannel 1996). Hypertension commonly clusters with other CVD risk factors 
(Kannel 1996).  
Individuals with lower socioeconomic position are more prone to have a fatal 
coronary or ischemic stroke event than those with a high socioeconomic status 
(Salomaa et al. 2001). Socioeconomic factors were observed to explain 30% 
(women) to 50% (men) of the difference in CHD mortality in Finland (Salomaa et 
al. 2001). Low socioeconomic status has also been shown to increased the risk for 
ischemic stroke events (36%) and mortality (56%) (Jakovljevic et al. 2001). Physical 
activity, occupational or leisure-time, has a positive effect on HDL, blood pressure, 
and body-mass index (BMI) in a Finnish study, reducing CVD risk in several ways 
(Barengo et al. 2006). 
 
2.3.1. Dyslipidemias 
The lifetime risk for CHD increases substantially with TC levels (Stamler et al. 
2000). According to Lloyd-Jones et al. (2003), the lifetime (from 40 to 80 years) 
CHD risk figures with TC levels of <5.2 mmol/l, 5.2 – 6.2 mmol/l, and <6.2 mmol/l 
were 31%, 43%, and 57% for men, and 15%, 26%, and 33% for women, 
respectively.  
Familial combined hyperlipidemia (FCHL) patients have elevated TC or TG or both, 
and are at substantial risk for early coronary event; FCHL is seen in approximately 
20% of CHD patients <60 years (Goldstein et al. 1973, Nikkilä and Aro 1973). 
Besides hypertriglyceridemia and hypercholesterolemia, other dyslipidemias, such 
as hyperapobetalipoproteniemia (Sniderman et al. 1980, Brunzell et al. 1983), 
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elevated small, dense LDL particles (Austin et al. 1990, Hokanson et al. 1993), and 
low HDL cholesterol (de Graaf and Stalenhoef 1998), as well as disturbances in 
glucose metabolism, such as poor glucose tolerance (Hunt et al. 1989, Aitman et al. 
1997) and insulin resistance (Pihlajamäki et al. 2000), are common FCHL-related 
features. The FCHL phenotype thus overlaps considerably with the phenotype of 
metabolic syndrome (Ayyobi and Brunzell 2003). The prevalence of FCHL is 1-6% 
in the western countries (Suviolahti et al. 2006).  
Traditionally, TC and LDL levels have been the key indicators of CVD risk, and 
major guidelines like the National Cholesterol Education Program Adult Treatment 
Panel III (ATPIII) (NCEP 2001) are based on these markers. Recent findings, 
however, highlight apolipoprotein B (ApoB) and the ApoB/ ApoA-1 ratio as more 
accurate predictors of CVD (Barter et al. 2006). All atherogenic lipid particles – 
VLDL, IDL, LDL, and lipoprotein a (Lp(a)) – contain ApoB-100 and chylomicrons 
contain ApoB-48. The total number of atherogenic particles is suggested to reflect 
CVD risk better than LDL alone, highlighting the role of ApoB (Barter et al. 2006). 
ApoB was observed to predict 10-year CVD risk independently from the traditional 
factors (Kiechl et al. 2007). Elevated TC, LDL, and ApoB also contribute to the risk 
of ischemic stroke events (Walldius et al. 2006). Controversial results have been 
reported on Lp(a) and the risk of CHD (Jauhiainen et al. 1991, Alfthan et al. 1994, 
Danesh et al. 2000, Murase et al. 2007).  
HDL cholesterol has several anti-atherogenic roles. As a key player in reverse 
cholesterol transport, HDL carries excess cholesterol from tissues to liver, 
decreasing the amount of circulating cholesterol. HDL also acts as an antioxidant 
(Navab et al. 2001). Low HDL cholesterol concentration (<0.9 mmol/l) is an 
independent CVD risk factor (Schaefer et al. 1994).  
Dyslipidemias are mainly complex genetic disorders where genes play a role among 
environmental factors.  Life-style factors affecting the cholesterol levels comprise 
smoking, alcohol consumption, physical activity, gender, and age.  The genetics of 
dyslipidemias is discussed in chapter 3.2.1. 
 
2.3.2. Obesity, metabolic syndrome, and type 2 diabetes 
The importance of diabetes and obesity as CVD risk factors is increasing steadily; 
while cholesterol levels are decreasing due to targeted health programs and 
pharmaceutical use, obesity and diabetes rates are constantly growing because of poor 
diet and physical inactivity (Smith 2007). Over 50% of Americans are overweight 
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(Smith 2007). In Finland, approximately 20% of adults have BMI exceeding 30kg/m2 
(Laatikainen et al. 2003). The risk for type 2 diabetes (T2DM) increases exponentially 
with BMI; women with BMI >31 kg/m2 had about 40 times and women with BMI > 
35kg/m2 about 90 times higher risk for T2DM lean lean (BMI <21 kg/m2) women 
(Colditz et al. 1995). In men with BMI >35 kg/m2, a 40-fold T2DM risk compared 
with lean men has been reported (Chan et al. 1994). Obesity increases the risk for 
CVD also by predisposing to dyslipidemias (Devroey et al. 2004), hypertension 
(Huang et al. 1998), and inflammation (Darvall et al. 2007). 
Metabolic syndrome (MetS) is characterized as a clustering of cardiovascular risk 
factors. The diagnostic criteria include different combinations of central obesity, low 
HDL cholesterol, elevated TG, elevated fasting glucose or insulin resistance, and 
hypertension. Several different definitions for MetS exist (Table 3). Definitions of 
the World Health Organization (WHO) (WHO 1999) and the European Group for 
the Study of Metabolic Syndrome (EGIR) (Balkau et al. 2002) are glucocentric, 
highlighting insulin resistance as a key feature. The International Diabetes 
Federation (IDF) (Alberti et al. 2006) describes central obesity as a critical factor, 
whereas the National Cholesterol Education Program Adult Treatment Panel III 
(NCEP 2001) includes two lipid criteria instead of one.  
Table 3. Definitions for metabolic syndrome. Male- and ethnic-specific values 
shown. 
 ATPIII IDF   WHO a EGIR 
 3 or more of the 
following factors: 
Waist grid > 94 cm 
with two or more 
of the following: 
Glucose 
intolerance, IGT or 
insulin resistance 
with  two of the 
following: 
Insulin resistance 
with two or more 
of the following: 
Central obesity Waist grid >102cm - Waist-hip ratio 
>0.9 or BMI > 30 
kg/m2 
Waist grid > 94 cm 
Triglycerides >1.7 mmol/l b >1.7 mmol/l b >1.7 mmol/l b >2.0 mmol/l b 
HDL-cholesterol <1.03 mmol/l b <1.03 mmol/l b <0.9 mmol/l b <1.0 mmol/l b 
Blood pressure >130/> 85 mmHg c >130/>85 mmHg c >140/> 90 mmHg c >140/> 90 mmHg c 
Fasting glucose       >5.6 mmol/l >5.6 mmol/l - >6.1 mmol/l 
a WHO definition also includes microalbuminuria as a criterion  b Or lipid lowering medication  c Or 
hypertension treatment   d Or previously diagnosed type II diabetes   e With non-diabetic individuals 
 
Opinions vary as to which of the various definitions is the best. The ATPIII 
definition does not require specific measurements for insulin resistance, and is 
therefore probably the most useful in clinical practice. Lakka and colleagues (2002) 
observed that the ATPIII definition was less consistent in predicting CVD and all-
cause mortality in men. Marchesini and colleagues (2004), in turn, suggested that 
ATPIII may predict future coronary events in T2DM patients better than the WHO 
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definition, and Tong et al. (2007) noted that ATPIII predicts future CHD better than 
the IDF definition. The WHO definition is proposed to have high sensitivity and 
specificity in predicting future diabetes in MetS patients (Laaksonen et al. 2002).  
Metabolic syndrome is known to predispose to T2DM and is associated with a 2- to 
4-fold risk for CVD events and mortality (Lakka et al. 2002, Sundström et al. 2006). 
The mechanisms underlying the contribution of MetS to CVD risk are, however, 
incompletely understood. Thrombosis is suggested to act as a link between MetS 
and CVD. Insulin resistance can be viewed as a pro-thrombotic state, characterized 
by endothelial activation, hypercoagulation, and hypofibrinolysis (Darvall et al. 
2007). Obesity, predisposing to insulin resistance and a key feature in MetS, 
promotes the secretion of several pro-thrombotic substances and directly promotes 
inflammation and endothelial dysfunction, components of increased thrombosis 
(Darvall et al. 2007). Platelets express insulin receptors. In nonobese, healthy 
subjects, insulin prevents platelet aggregation (Trovati et al. 1995), but 
antiaggregation is suggested to be disturbed in obese (Trovati et al. 1995) and 
hypertensive (Touyz et al. 1994) subjects. Abnormal insulin actions, linked to 
obesity, are suggested to increase thrombogenic activities by reducing platelet 
inhibition and interaction with collagen (Westerbacka et al. 2002). Elevated glucose 
levels possibly also increase thrombus formation via tissue factor release (Sambola 
et al. 2003).  
 
People with T2DM have 2-4 times increased risk for coronary events and a 4-fold 
risk for CHD death (Manson et al. 1991, Koskinen et al. 1992, Haffner and Cassels 
2003). Individuals suffering from MI also were at 2- (men) to 4-fold (women) risk 
of developing diabetes compared with the population free of MI (Pajunen et al. 2005 
b). The risk for stroke events is double in the diabetics (Manson et al. 1991, 
Wannamethee et al. 1999), and diabetes significantly worsens the prognosis of 
ischemic strokes (Kaarisalo et al. 2005). 
 
2.3.3. Molecular markers 
Several molecular markers are associated with the risk of cardiovascular events. 
Fibrinogen is one of the most significant hemostatic CVD predictors (Voetsch and 
Loscalzo 2004, Kannel 2005, Rajecki et al. 2005, Smith et al. 2005). People with 
fibrinogen levels in the highest quartile have approximately double the risk for both 
MI and ischemic stroke events as those with fibrinogen in the lowest quartile 
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(Voetsch and Loscalzo 2004). Increased fibrinogen levels are associated with such 
CVD risk factors as obesity, smoking, advanced age, physical inactivity, 
hypertension, dyslipidemias, and diabetes (Voetsch and Loscalzo 2004, Kannel 
2005). Fibrinogen is also an acute-phase reactant together with C-reactive protein 
(CRP), and may contribute to CVD via inflammatory response (Kannel 2005). 
Elevated CRP concentrations are associated with the risk of cardiovascular diseases 
(Ferranti and Rifai 2007). Homocysteine may not predict the risk of CHD in the 
general Finnish population (Alfthan et al. 1994, Voutilainen et al. 2000, Voutilainen 
et al. 2007), but elevated homocysteine concentrations may predict CHD events in 
individuals with diabetes (Soinio et al. 2004), and are assotiated with the risk of 
stroke (Virtanen et al. 2005).  
Fibrinogen and plasminogen concentrations have showed association with all CVD 
events, but not with isolated strokes in a Finnish study (Rajecki et al. 2005). Levels 
of PLAT antigen and PAI1 are associated positively with the degree of carotic 
stenosis, an important predictor for ischemic stroke events (Soinne et al. 2005). High 
PAI1 expression is seen in atherosclerotic lesions especially in people with diabetes 
(Aso 2007). High levels of coagulation factors VIIa and VIII, as well as von 
Willebrand factor, are associated with atherosclerosis (Meade et al. 1986).  
A neuroprotective role has been suggested for activated protein C. The issue was 
reviewed by Griffin et al. (2006). High APC concentrations are associated with 
lower incidence of ischemic strokes, whereas the ischemic stroke patients have low 
APC concentrations. Protein C deficiency has been described in several case reports 
in patients having arterial thrombotic events (Cakir et al. 2002, Tiong et al. 2003).  
Activated protein C, in response to thrombin formation, contributed also to 
reperfusion hemodynamics after cardiac surgery (Raivio et al. 2007).  
Several studies have reported an association of high soluble ICAM1 (sICAM1) 
concentration with CHD (Haugt et al. 1996, Hwang et al. 1997, Malik et al. 2001) or 
with atherosclerosis (Jenny et al. 2006). High sICAM is also suggested to contribute 
to CHD in relation to low soluble thrombomodulin (sTM) (Wu et al. 2003). The 
relationship of soluble VCAM1, E selectin, and P selectin is less well established 
(Hwang et al. 1997, Malik et al. 2001). High sICAM1 levels have shown association 
with ischemic stroke events (Simundic et al. 2004, Ehrensperger et al. 2005) and 
with poor survival after a stroke (Wang et al. 2006, Blum et al. 2006). High sICAM1 
also predicted future stroke events in CHD patients (Tanne et al. 2002), and 
sICAM1 may prove a marker for silent cerebral infarctions (Kawamura et al. 2006). 
Elevated soluble VCAM1 and soluble E-selectin concentrations may be associated 
 28 
with the risk of stroke (Simundic et al. 2004, Blum et al. 2006), and elevated 
expression of ICAM1 and VCAM1 (Davies et al. 1993), as well as that of E and P 
selectins (Dong et al. 1998), has shown association with the risk of atherosclerosis. 
However, Wang et al. (2006) reported that soluble VCAM1 and E selectin may not 
be associated with the risk of stroke, and Nuotio et al. (2003) reported a negative 
association of the expression of adhesion molecules ICAM1, VCAM1, and selectins 
in symptomatic carotic stenosis plaques.  
The relationship of sTM with CVD is complex. Low sTM may contribute to the risk 
of MI (Salomaa et al. 1999, Wu et al. 2003), but elevated sTM is suggested to relate 
to the progression of atherosclerosis in CHD patients (Blann et al. 1997). Olivot et 
al. (2004) suggested that high sTM may be protective for ischemic stroke in the 
individuals previously free of stroke, but in contrast, in those with prior stroke 
events, reflect the fatal outcome. Recently Zhang et al. (2007) reported that high 
sTM may relate to the risk of ischemic stroke, whereas Jauch et al. (2006) stated that 
sTM may not contribute to ischemic strokes. Soluble thrombomodulin 
concentrations may reflect natural anticoagulation in the healthy individuals, but in 
the diseased individuals, sTM may relate to extend of the disease (Olivot et al. 2004, 
Constans and Conri 2006). 
Although several molecular markers show association with the risk of 
cardiovascular outcomes, the clear predictive value of these factors remains unclear. 
Adhesion molecules ICAM1, VCAM1, and E and P selectins (Malik et al. 2001), 
and CRP (Lloyd-Jones et al. 2006 b) may not add substantially to the traditional risk 
factors in predicting CHD, and according to Matijevic and Wu (2006), the true 
causal relationship between the markers like fibrinogen, PAI1, von Willebrand 
factor, FVIII, and sTM with stroke events has not been established.  
 
Cardiovascular diseases belong genetically to common traits, where the interplay of 
genetic and environmental factors influences the disease outcome. The genetic 
component of CVD is discussed in detail in the next section. Figure 5 illustrates the 
complex interplay of the risk factors in atherogenesis. 
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Figure 5. Complex interplay of cardiovascular risk factors in atherogenesis, finally 
manifesting as cardiovascular events.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. CARDIOVASCULAR GENETICS 
Genetic factors contribute significantly to the epidemiology of both CHD and 
ischemic stroke events. Marenberg et al. (1994) estimated in a large twin study that 
when one twin suffered a fatal MI, the risk for a fatal MI for the other monozygotic 
twin was 8-fold, and for a dizygotic twin nearly 4-fold when compared with the risk 
of the general population. Family history of stroke or transient ischemic attack 
increased the stroke risk 1.5–2.5-fold (Goldstein et al. 2006). Heritability measures 
the degree the genetic factors explain of the variance in a phenotype. The heritability 
of death from stroke in Danish families was approximately 30% (Bak et al. 2002). 
While environment affects the majority of well-established factors contributing to 
CVD risk (Table 2), these factors themselves belong genetically to complex traits: 
Heritability estimates lay between 30 and 70 for obesity (Loos and Bouchard 2003), 
between 40 and 80 for T2DM (Permutt et al. 2005), between 30 and 50 for 
hypertension (Koskenvuo et al. 1992, Hong et al. 1994), and between 40 and 80 for 
all LDL, TC, and HDL levels (O’Connell et al. 1988, Heller et al. 1993). Evidence 
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has also recently accumulated for genetic background of nicotine dependency and 
smoking behavior (Li et al. 2006, Loukola et al. 2007).  
Moreover, there is considerable overlap in the genes predisposing to different traits, 
further complicating the complexity of CVD genetics. For example, upstream 
transcription factor -1 (USF1) variants are associated with FCHL, different 
dyslipidemias, diabetes, and CVD, and ICAM1 variants are related to CVD, type 1 
diabetes, asthma, and different cancers. Both genes are discussed in detail below.  
 
3.1. Rare and common cardiovascular and metabolic traits 
Viewing genes linked to rare monogenic CVD traits may help to unravel the 
complicated background of common diseases. Although many of the causative 
mutations are extremely rare, often even family-specific, these unique disease forms 
have provided valuable information on the pathophysiology involved in common 
disease processes (Peltonen et al. 2006).  
MODY represents a familial form of diabetes. The disease manifests in early 
adulthood, accounting for 2-5% of all diabetes cases (Ledermann 1995). Six 
different genes have been identified as contributing to MODY, all critical for 
pancreatic cell development (McCarthy 2004). Reflecting the underlying mutation, 
MODY cases express genetic and clinical heterogeneity (Stride and Hattersley 
2002). Studies on MODY have shed light on the pathogenesis of diabetes also in a 
wider setting.    
USF1 gene provides a clear example of how studies ascertained for special rare 
families can pinpoint candidate genes for common traits. Chromosomal region 
1q21-23 was first linked to FCHL in Finnish families (Pajukanta et al. 1998). Closer 
studies on the region revealed a new FCHL candidate gene, USF1 (Pajukanta et al. 
2004). Subsequent studies provided evidence for functional significance of the 
associated allele (Naukkarinen et al. 2005) and supported the influence of USF1 
variants on CVD and mortality also at a population level (Komulainen et al. 2006). 
Interestingly, other studies have reported an association of USF1 single nucleotide 
polymorphisms (SNPs) also with MetS and T2DM, suggesting some genetic overlap 
of these disease groups (Gibson et al. 2005, Ng et al. 2005).  
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3.2. Some CVD-related loci 
Several traits contributing to formation of atherosclerosis, giving rise to CVD exist. 
The target genes of this thesis contribute to dyslipidemias (USF1), thrombosis (F5, 
PROC, THBD), and endothelial dysfunction (ICAM1). The most important genes of 
these traits in the perspective of cardiovascular outcomes are discussed in the 
following sections.  
 
3.2.1.  Genes related to dyslipidemias 
Characteristic of dyslipidemia genes is an association with more than one lipid trait. 
Many genes have first been linked to rare familial disorders. One of the most famous 
examples is LDL receptor gene (LDLR), whose point mutations predispose to 
familial hypercholesterolemia (Hegele 2007). More recently, LDLR has been linked 
to Alzheimer’s disease (AD) (Kong et al. 2006, Bertram et al. 2007) and HDL and 
LDL traits (Knoblauch et al. 2004). ATP-binding cassette -1 (ABCA1) gene was first 
identified in rare HDL-deficiency with autosomal recessive inheritance, Tangier’s 
disease (Brooks-Wilson et al. 1999). Subsequently, ABCA1 has been associated with 
low HDL concentrations in the general population, as well as with AD (Katzov et al. 
2004) and CVD (Clee et al. 2001, Frikke-Schmidt et al. 2005). APOE epsilons are 
among the most studied genetic variants in dyslipidemias and CVD (reviewed by 
Eichner 2002). The epsilons are associated with TC, LDL, and ApoB 
concentrations, as well as with AD, CVD, stroke, and peripheral artery disease.  
Familial combined hyperlipidemia is currently a hot topic in lipid genetics. The 
genetic background of FCHL is complex (reviewed by Naukkarinen et al. 2006, 
Suviolahti et al 2006). In family studies, three main chromosomal regions, 1q21-23, 
11p, and 16q22-24, have been linked to FCHL. Replicated evidence for association 
with FCHL exist for lipoprotein lipase gene (LPL) (Naukkarinen et al. 2006, 
Suviolahti et al 2006), apolipoprotein A1/C3/A4/A5 gene cluster 
(APOA1/C3/A4/A5) (Naukkarinen et al. 2006, Suviolahti et al 2006), and USF1 
(Pajukanta et al. 2004, Coon et al. 2005, Huertas-Vazquez et al. 2005, van der 
Vleuten et al. 2007).  
USF1 has lately been one of the most studied CVD-related genes. As a transcription 
factor, it influences some 40 genes, many participants of body lipid or glucose 
metabolism (Naukkarinen et al. 2005). USF1 was first linked to dyslipidemias in a 
Finnish sample of FCHL families (Pajukanta et al. 2004), where two USF1 SNPs were 
associated with TG and TC levels in males. Subsequently, several family studies have 
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indicated positive associations of USF1 SNPs and haplotypes with different 
dyslipidemias (Coon et al. 2005, Huertas-Vazquez et al. 2005, Komulainen et al. 2006, 
van der Vleuten et al. 2007). USF1 variants also showed association with T2DM/MetS 
in Chinese families (Ng et al. 2005), but results from a French family sample, were by 
contrast, negative (Gibson et al. 2005). At a population level, USF1 variants were 
associated with CVD events and mortality in women in two Finnish population 
cohorts (Komulainen et al. 2006). In males, however, population studies on USF1 and 
T2DM/MetS and CVD have yielded negative results (Gibson et al. 2005, Ng et al. 
2005, Komulainen et al. 2006, Zeggini et al. 2006). Functional studies suggest that 
USF1 downregulates the APOE gene in individuals with dyslipidemias and may in this 
way contribute to atherogenesis (Naukkarinen et al. 2005).  
Despite the abundance of genes related to different dyslipidemias, direct 
associations with CVD events are scarce; replicated evidence exists only for APOE 
(Eichner 2002) and ABCA1 (Clee et al. 2001, Frikke-Schmidt et al. 2005), followed 
by single findings with LPL (Leshinsky-Silver et al. 2006) and USF1 (Komulainen 
et al. 2006). With APOA1/C3/A4/A5, the findings regarding CVD have been 
inconsistent (reviewed by Lai et al. 2006).  
It is nevertheless worth pointing out that all of the strong FCHL candidates have 
shown some association with CVD. Other studies have in addition suggested a 
potential common genetic background for FCHL, metabolic syndrome, and T2DM 
(Gibson et al. 2005, Ng et al. 2005). These findings make the FCHL-linked genes 
tempting candidates for common traits beyond familial dyslipidemias. Table 4 lists 
some important genes linked to dyslipidemias.  
 
3.2.2. CVD-related thrombosis and cell adhesion molecule genes  
Genes related to arterial thrombosis include blood coagulation factors, fibrinolytic 
factors, and platelet-membrane receptors (reviewed by Lane and Grant 2000, 
Voetsch and Loscalzo 2004). Characteristic of thrombosis genes and CVD is that 
although plasma concentrations of various hemostatic agents are associated with 
CVD, the link between soluble protein concentration and gene variants, and further, 
with gene variants and CVD is often somewhat unclear.  
Elevated fibrinogen levels are consistently linked with increased CVD risk. 
Although fibrinogen gene variants are associated with fibrinogen levels, the 
relationship of the SNPs and CVD is less well established (Lane and Grant 2000). 
Several fibrinogen- (FGB) polymorphisms are suggested to be associated with 
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CVD, physiologically the most significant being the binding-site altering promoter 
region SNPs -445G/A and -854G/A (Voetsch and Loscalzo 2004). Results from very 
large studies on FGB SNPs and CVD have, however, been negative (Lane and Grant 
2000, Voetsch and Loscalzo 2004). Same is true for fibrinogen- polymorphism 
Thr312Ala (Voetsch and Loscalzo 2004).   
Table 4. Some genes linked to dyslipidemias. 
GENE TRAIT REFERENCE 
ABCA1 HDL, CVD, AD, Tangier’s disease                       1-4 
APOA2      HDL 5-6 
APOA1/C3/A4/A5       FCHL, HDL, TG                                                   7-9 
APOB HDL, LDL, TC 11 
APOE ApoB, LDL, TC, CVD 9, 12-14 
CETP HDL, LDL, HDL/LDL, CVD 9, 11, 15 
FOXC2   BMI, HDL, TG, obesity 16 
HNF1A   T2DM 17 
HNF4A    T2DM, TC, TG, MetS, glucose markers                     18-22 
LCAT FCHL, HDL                                                            23-24 
LDLR   FH, AD, HDL, LDL                                                     11, 25-26 
LEPR   FCHL, ApoB, HDL 27-29 
LIPC (HL)                   HDL, ApoB, TC                                                          30-31 
LPL HDL, Familial hyperchylomicronemia, CVD, AD      32-34 
PCSK9 LDL 35-36 
PPARA FCHL, LDL, MetS 9, 37 
SOAT1 HDL, AD                                                               9, 32 
TNFRSF1B FCHL 38 
USF1 FCHL, LDL, TC, TG, MetS, BMI, lipolysis, CVD     39-47 
References: 1) Brooks-Wilson et al. 1999, 2) Clee et al. 2001, 3) Cohen et al. 2004, 4) Frikke-Schmidt et al. 
2005, 5) Lilja et al. 2002, 6) Welch et al. 2004, 7) Gagnon et al. 2003, 8) Pennacchio et al. 2003, 9) Klos et al. 
2006, 10) Lai et al. 2006, 11) Knoblauch et al. 2004, 12) Eichner 2002, 13) Martins et al. 2006, 14) Stengard et 
al. 2006, 15) Leshinsky-Silver et al. 2006, 16) Carlsson et al. 2004, 17) Winckler et al. 2005, 18) Hansen et al. 
2005, 19) Damcott et al. 2004, 20) Love-Gregory et al. 2004, 21) Silander et al. 2004, 22) Weissglas-Volkov et 
al. 2006, 23) Zhang et al. 2004, 24) Aouizerat et al. 1999, 25) Kong et al. 2006, 26) Bertram et al. 2007, 27) 
Allayee et al. 2002, 28) Norman et al. 1998, 29) van der Vleuten et al. 2007, 30) Allayee et al. 2000, 31) 
Hoffer et al. 2000, 32) Papassotiropoulos et al. 2005, 33), 34) Leshinsky-Silver et al. 2006, 35) Cohen et al. 
2006, 36) Fasano et al. 2006, 37) Eurlings et al. 2003, 38) Geurts et al. 2000, 39) Pajukanta et al. 2004, 40) 
Coon et al. 2005, 41) Huertas-Vazquez et al. 2005, 42) van der Vleuten et al. 2007, 43) Komulainen et al. 
2006, 44) Putt et al. 2004, 45) Gibson et al. 2005, 46) Ng et al. 2005, 47) Zeggini et al. 2006. 
ABCA1: ATP-binding cassette -1; AD: Alzheimer’s disease; APOA2: Apolipoprotein A2; APOA1/C3/A4/A5: 
Apolipoprotein A1/C3/A4/A5 gene cluster; APOB: Apolipoprotein B; APOE:  Apolipoprotein E; CETP: 
Cholesterol ester transfer protein; FOXC2: Forkhead box C2; HNF1A: Hepatic nuclear factor -1; HNF4A: 
Hepatic nuclear factor -4; LCAT: Lecithin:cholesterol acyl transferase; LDLR: LDL receptor; LIPC (HL): 
Hepatic lipase; LPL: Lipoprotein lipase; PCSK9: Proprotein convertase subtilisin/kexin type -9; PPARA: 
Peroxisome proliferator-activated receptor ; SOAT1: Sterol o-acyltransferase -1; TNFRSF1B: Tumor necrosis 
factor receptor subfamily 1 member ; USF1: Upstream transcription factor -1. 
 
Coagulation factor VII (F7) variants, the most important ones being Arg353Gln, 
hypervariable region 4 (HVR4), -401G/T, and -402G/A, are estimated to explain 
about 30% of the F7 plasma level variation. Again, the connection of the F7 SNPs to 
the actual disease outcome, CVD events, is somewhat unclear (Lane and Grant 
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2000). FXIII Val34Leu has been repeatedly associated with decreased MI risk 
(Kohler et al. 1998, Wartiovaara et al. 1999).  
The Leiden mutation of coagulation factor V gene (F5) was characterized in 1994 
(Voorberg et al. 1994, Zöller et al. 1994). The polymorphism G1691A results to the 
substitution of arginine for glutamine at amino acid site 506, which acts as a 
cleavage site for APC. The F5 Leiden polymorphism creates APC resistance and 
strongly increases the risk for venous thrombosis. Heterozygotes for the F5 Leiden 
have approximately a three-fold risk, whereas for homozygotes, the risk is estimated 
to be over ten-fold (Lane and Grant 2000, Simmonds et al. 2001). Prevalence of the 
Leiden mutation in Caucasians ranges from 1% to 15% (Rees et al. 1995, Ridker et 
al. 1997, Franco et al. 1999), and the mutation is suggested to be present in 10-50% 
of the deep venous thrombosis cases (Franco et al. 2001). Additional mutations, 
such as a F5 haplotype H2R and other point mutations affecting the APC cleavage 
site, have also been described (Bernardi et al. 1997, Chan et al. 1998, Williamson et 
al. 1998).  
Studies on F5 Leiden and CVD have been controversial. The Leiden mutation and 
prothrombin (F2) G20210A polymorphism associated with CHD in a recent large 
meta-analysis (Ye et al. 2006). F5 is a large gene spanning over 70 kilobases (kb), 
located at chromosome (chr) 1q23. Data on gene variants other than the Leiden 
mutation are scarce.  
Plasminogen activator inhibitor -1 contributes to thrombosis as a potent inhibitor of 
tissue plasminogen activator. High PAI1 concentrations are associated with CVD 
risk, especially in persons with diabetes (Lane and Grant 2000). PAI1 gene promoter 
variant -675 4G/5G has been widely studied, but although this variant contributes to 
soluble PAI1 levels, the association with CVD remains unclear (Lane and Grant 
2000, Ye et al. 2006). Similarly, PLAT SNP -7351C/T has been studied extensively, 
but the association with CVD is unclear (Lane and Grant 2000). A recent study 
suggested that two PLAT haplotypes increase CVD risk (Kathiresan et al. 2006).  
Of thrombomodulin (THBD) variants, Ala25Thr has been associated with MI (Doggen 
et al. 1998), but not with cerebrovascular disease (Warner et al. 2000). An association 
of Ala455Val with MI was reported by Ireland et al. (1997), with CHD by Wu et al. 
(2001), and with ischemic stroke by Cole et al. (2004). Konstantoulas et al. (2004) 
found the combination of -1208--1209TTdelTT and Ala455Val to be associated with 
MI in men. Chao et al. (2004) stated that -33G/A vatiant may relate to premature MI. 
Ohlin et al. (2004) concluded that THBD may not contribute to acute coronary 
syndrome. The role of thrombin activatable fibrinolysis inhibitor gene variants in CVD 
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is unclear (Voetsch and Loscalzo 2004). 5,10-methylenetetrahydrofolate gene 
(MTHFR) polymorphism 677C/T contributes to homocystenemia, but the relation with 
CVD is unclear (Voetsch and Loscalzo 2004).  
Reitsma et al. (1995) have described over 160 polymorphisms at the PROC locus on 
chr 2q13-14. However, little is known of their relation to thrombophilia. Spek et al. 
(1995) introduced three SNPs on the promoter region of the gene contributing to 
protein C level. However, Buil et al. (2004) estimated these SNPs to account for 
only 6% of the variation in plasma protein C levels, and reported a new influencing 
locus on chr 16.  
A recent study suggested an association of ICAM1 Lys469Glu variant (Podgoreanu 
et al. 2006) with MI after cardiac surgery. Previously McGlinchey et al. (2004) 
found no association of this variant with CHD. Recent reports suggest that VCAM1 
(Miyoshi et al. 2007) SNPs may contribute to the development of atherosclerosis. 
The relation of SELP variants with CHD and stroke risk is unclear (Zee et al. 2004, 
Volcik et al. 2006, Volcik et al. 2007). Results on the role of the glycoprotein (GP) 
family variants in CVD have been controversial. In a recent large meta-analysis, no 
association was seen with any of the most studied GP variants GPIa C807T, GPIb 
T-5C, GPIIIa C1561T (Ye et al. 2006).  
Taken together, although concentrations of several hemostatic factors contribute to 
CVD risk, the same seems to be true only with very few genetic variants; in recent 
large studies, only the F5 Leiden mutation and F2 20210G/A variant have provided 
positive results. This might reflect Reitsma’s (2004) postulate that inherited 
hypercoaguability states, such as the factor V Leiden mutation, increase the 
probability for the first thrombosis event; in the arterial side, this is true in the 
absence of inflammation and atherosclerosis, i.e. very rarely. When atherosclerosis 
advances, inherited hypercoaguability loses importance, similar to recurrent venous 
thrombosis. Table 5 summarizes the most studied hemostatic variants.  
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Table 5. Gene variants of thrombosis genes and cell adhesion molecule genes 
showing association with CVD events.  
Gene                  Polymorphism          Reference 
F2    20210G/A                                                    Ye et al. 2006 
F5    Arg506Gln (The Leiden mutation)             Ye et al. 2006 
F7    Arg353Gln, HVR4, -401G/T, -402G/A Voetsch and Loscalzo 2004 
FXIII       Val34Leu Voetsch and Loscalzo 2004 
FGB     -445G/A, -854G/A, Bcl1, Thr312Ala           Voetsch and Loscalzo 2004 
GPIa   807C/T                                                         Ye et al. 2006 
  Voetsch and Loscalzo 2004 
GPIb      -5T/C, Thr145Met                                        Voetsch and Loscalzo 2004 
GPIIIa            Leu33Pro Ye et al. 2006                                     
  Voetsch and Loscalzo 2004 
ICAM1      Lys469Glu   Podgoreanu et al. 2006 
MTHFR   677C/T                                                         Voetsch and Loscalzo 2004 
PAI1       -675 4G/5G                                                   Lane and Grant 2000 
PLAT -7351C/T                                                      Voetsch and Loscalzo 2004 
  Kathiresan et al. 2006 
TAFI       Ala147Thr, 1542C/G                                    Voetsch and Loscalzo 2004 
THBD   Ala25Thr  Doggen et al. 1998  
 Ala455Val     Wu et al. 2001 
 -1208--1209TTdelTT                                     Ireland et al. 1997 
  Konstantoulas et al. 2004 
F2=Prothrombin, F5=Coagulation factor V, F7= Coagulation factor VII, FXIII= Coagulation factor XIII, 
FGB=Fibrinogen , GPIa=Integrin -2, GPIb=Glycoprotein Ib, platelet, -polypeptide, GPIIIa=Integrin -3, 
ICAM1=Intercellular adhesion molecule -1, MTHFR=5,10-methylenetetrahydrofolate reductase, 
PAI1=Plasminogen activator inhibitor -1, PLAT=Tissue plasminogen activator, TAFI= Thrombin activatable 
fibrinolysis inhibitor, THBD=Thrombomodulin.  
 
3.2.3. Genes related to ischemic stroke events 
The putative candidate genes for ischemic stroke events comprise genes related to 
hypertension, inflammation, thrombosis, and dyslipidemias. Accordin to Humpries 
and Morgan (2004), the most promising stroke candidates include APOE, 
angiotensin converting enzyme, and MTHFR. Evidence replicated in several studies 
exists for these three genes, although some studies have also shown negative results 
(Humpries and Morgan 2004). A recent meta-analysis by Ariyaratnam et al. (2007) 
stated that strong evidence exists for the same three genes also in Asians of non-
European origin. 
 
Other putative genes contributing to stroke events include interleukin 6 (IL6), 
cholesterol ester transfer protein (CETP), hepatic lipase (HL), and paraoxinase 
(PON1) (Humpries and Morgan 2004), followed by PAI1 (Ariyaratnam et al. 2007), 
LPL (Shimo-Nakanishi et al. 2001), gene encoding 5-lipoxygenase activating 
protein (ALOX5AP) (Helgadottir et al. 2004, Worrall and Mychaleckyj 2006), and 
phosphodiesterase 4D (PDE4D) (Gretarsdottir et al. 2003).  
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4. STRATEGIES TO IDENTIFY GENES FOR CARDIOVASCULAR TRAITS 
 
4.1. Studying complex diseases    
Cardiovascular diseases belong to complex traits, where the disease outcome is 
affected by environmental as well as genetic factors. The genetic structure of 
complex traits is still largely unknown, and several competing hypotheses prevail. 
According to the common variant – common disease hypothesis, the genetic basis of 
complex traits consists of several common but low-penetrance predisposing loci: 
The numerous risk variants occur frequently in the population, but each of them 
likely has only a modest effect on the disease phenotype (Collins et al. 1997). 
According to the competing heterogeneity model, the structure of complex traits is 
based on rare alleles with major phenotypic effects, whereas the “neutral” 
hypothesis suggests that the spectrum of disease alleles in complex traits reflects that 
of all the genomic variants (Wang et al. 2005).  
In addition to the issue of unknown inheritance, several other factors complicate the 
study of complex traits (Table 6). Such genetic factors include genetic 
heterogeneity, diversity in allele frequencies across different populations, 
pleiotrophy (the same genetic variant is responsible for more than one disease 
phenotype), and epistatic coeffects between several genes. Of clinical features, 
uncertain and diverse phenotypes, difficulties in disease diagnostics, and late disease 
onset further complicate the study designs. In addition, technical hinders such as 
genotyping costs and accuracy, and statistical issues like multiple testing should be 
taken into account, also bearing publication bias towards positive results in mind. 
(Lander and Schork 1994, Risch 2000). 
 
 
4.2. Gene identification strategies 
Effective identification of genes underlying complex traits is likely to require the use 
of several different techniques (Miller et al. 2007). According to Lander and Schork 
(1994), the main strategies in the search for novel loci in common diseases are 
linkage analyses, association analyses, and experimental animal models. 
Accordingly, Glazier et al. (2002) proposed a stepwise strategy for gene 
identification in complex traits: First, a linkage study of the whole genome is 
performed.  Next, area under the linkage peak is fine-mapped to narrow down the 
linked region.  Candidate genes in the region can be sequenced to define allelic 
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variants. Alternatively, markers for the fine-mapping can be selected from an allelic 
variation database according to the haplotype block assumption (discussed below). 
Finally, functional studies are performed with the associated alleles. Advantages and 
disadvantages of the different gene identification methods introduced below are 
presented in Table 7.  
 
Table 6. Several factors complicate gene identification in common disorders 
compared with monogenic traits. These factors can be divided into genetic, 
phenotypic, and other factors related to statistical and technical issues.  
 SOME FACTORS COMPLICATING THE STUDY OF COMPLEX TRAITS 
Genetic factors 
 
Unknown inheritance pattern  
Unknown allele frequencies 
Genetic heterogeneity 
Epistasis 
Phenotypic factors Diagnostic difficulties 
Late onset of a disease 
Pleiotrophy 
Phenocopies 
Unknown penetrance 
Statistical factors      Limited sample size 
Multiple testing 
Technical issues Genotyping costs 
Genotyping errors 
Publication bias       Negative results do not arouse sufficient interest to be published 
 
 
4.2.1. Linkage studies  
Linkage studies are a common way to search for new disease loci (Curtis et al. 
1995). A whole-genome linkage scan contains markers across the genome, analyzed 
in a family sample. Linkage studies look for co-segregation of a genetic marker and 
a trait.  Linkage studies are commonly divided into parametric or nonparametric 
methods. The parametric approach requires estimation of inheritance model and 
disease allele frequency and penetrance in the population. This is often difficult in 
complex traits, which more commonly rely on nonparametric methods, based on 
allele sharing between relatives sharing the same phenotype. In diseases with late 
onset, ancestral information is often lacking, and a large number of siblings are 
needed to gain sufficient power. This may prove problematic if the disease of 
interest is rare. In addition, the marker coverage of a whole-genome linkage scan is 
relatively poor for association purposes and requires further focusing with fine-
mapping after a positive linkage signal (Lander and Schork 1994, Glazier et al. 
2002, Miller et al. 2007). 
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4.2.2. Linkage disequilibrium and population isolates 
Two alleles from separate loci inherited together more often than expected by 
chance only are in linkage disequilibrium (LD). R2 is a measure for LD, reflecting 
correlation between two different variables. Several driving forces for LD exist, 
including population founder effects, recent mutations, and natural selection 
favoring certain alleles (Slatkin 1994). 
LD patterns and allelic spectra differ between populations. Small, long-isolated, and 
stable-sized founder populations are observed to hold extended LD distances 
compared with more heterogeneous populations (Laan and Pääbo 1997, Service et 
al. 2006). Isolated populations are also likely to possess fewer disease alleles and to 
express greater extend of allele-sharing around the disease allele (Peltonen et al. 
1999, Peltonen 2000, Varilo et al. 2003). LD patterns provide means of discovering 
linkage with a marker and a disease without genotyping the actual disease-causing 
locus (indirect association), reducing the number of markers necessary to cover the 
genome in a study. 
Population isolates have indeed been useful in mapping genes for rare monogenic 
diseases. Population isolates may prove useful also in complex traits (Collins et al. 
1997, Peltonen 2000, Amos 2007), although the case is likely to be less 
straightforward than with monogenic disorders, and the LD patterns around disease-
causing variants in founder populations may not differ extensively from mixed 
populations (Hirschhorn and Daly 2005). Isolated populations, however, hold an 
important advantage; the similarity of lifestyle factors likely reduces the noise in 
genetic studies (Peltonen 2000). 
 
4.2.3. The Finnish population and genetic studies 
The Finns as a population offer several advantages in the study of genetics. Finns 
are a typical isolated population. The country was inhabited in two major waves: 
The early settlement, approximately 2000 years ago, inhabited the southern part of 
the country, following the coastal line (Nevanlinna 1972, Varilo et al. 2003). The 
late settlement took place in the 16th century and was characterized by internal 
migration from a small region in the southeast of the country to northern and 
western parts, forming small, long-isolated and stable-sized subpopulations. Some of 
these subisolates present accumulation of certain disease alleles, giving rise to 
regional differences in the disease prevalence within the country (Pastinen et al. 
2001). The founder effect has facilitated the study of many monogenic traits 
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(Peltonen et al. 1999). In addition to the nearly 2000 years of isolation, bottlenecks 
such as wars and famines have molded the Finnish population and regional gene 
pools.  
The Finns also have other features that may pave the way in the study of monogenic 
and complex traits. The opinion of the well-educated population towards medical 
studies tends to be open-minded, yielding high study participation rates. Finland has 
high healthcare standards, and the relatively homogeneous education for medical 
professionals facilitates the disease diagnostics and phenotyping. Availability of 
medical and genealogical records dates back several hundred years. Table 8 
summarizes the main advantages.      
Table 8. The Finnish population is well suited well for genetic studies due to 
reduced genetic and environmental heterogeneity.  
ADVATAGENS OF THE FINNISH POPULATION IN GENETIC STUDIES 
 
Reduced number of disease alleles: 
 
Founder effect 
Isolation 
Bottlenecks 
Accurate healthcare data and sampling: Homogeneity in disease diagnostics 
High standard of medical records 
Long availability of genealogical records    
Homogeneity in lifestyle factors  
Positive attitude towards medical research  
 
4.2.4. Haplotypes 
Completion of the Human Genome Project has opened new gateways to genetic 
research, one of the most significant being the the International HapMap project. 
HapMap’s aim is to produce a physical map of the human genome by providing a 
limited number of “tag-variants” across the genome (www.hapmap.org). Tag-
variants are mainly SNPs, i.e. tag-SNPs, but also include small insertions and 
deletions. The idea of HapMap is based on uneven distribution of recombinations in 
the genome, creating distances of genomic sequence, “blocks”, where 
recombinations are only seldom observed (Daly et al. 2001). The SNPs in each 
block are in substantial LD. Cover most genetic variation at a given locus is 
therefore possible by genotyping one SNP in each block of the locus.  
Each tag-SNP represents a block, tagging one haplotype at the locus. Haplotype 
refers to the nucleotide structure in a single DNA strand. Within each haplotype 
block, increased LD and reduced recombination rate are observed. According to the 
HapMap theory, one or a few polymorphism(s) from each block is therefore 
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sufficient to capture most of the common variation within a block. This theory is 
based on several simplifications and has also been criticized (Terwilliger and 
Hiekkalinna 2006).  
The tag-SNP may itself prove a causative variant for a disease (direct association). 
Alternatively, the tag-SNP can be in LD with the actual causative variant (indirect 
association). Figure 5 gives an example of tag-SNPs defining haplotypes at a gene 
locus. 
 
Figure 6. The imaginary gene locus contains 8 SNPs, which can be divided into 
three haplotype blocks: SNP 2 is in substantial LD with SNPs 1 and 3, and therefore 
tags block 1. SNP 5 tags haplotype block 2, representing SNPs 4 and 6. SNP 8 tags 
the third haplotype block. Thus, tag-SNPs 2, 5, and 8 cover the allelic variants of 
this gene locus. Together, these tag-SNPs form three haplotypes, ACT, GCG, and 
GTT. Allele A of SNP 2 is only present in haplotype ACT, whereas allele G of SNP 2 
appears in the other two haplotypes. The Allele A therefore tags the haplotype ACT: 
Allele A of SNP 2 always appears together with allele C of SNP 5 and allele T of 
SNP 8. 
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4.2.5. Candidate gene studies 
Linkage studies are utilized to define a chromosomal region linked with the disease 
studied. The linked region may contain potential candidate genes for the disease. 
The region of interest can then be further addressed by fine-mapping, forming a tight 
marker map across the candidate gene locus to capture its allelic variation. 
Alternatively, interesting candidate genes can be selected based on their known 
functions. For example, soluble plasma coagulation factors involved in the clotting 
cascade contribute to thrombotic events, and the genes encoding these proteins are 
intriguing candidates for venous and arterial thrombosis.    
Association analysis is commonly used in candidate gene studies. In association 
analysis, allele frequencies of a marker are compared between the disease and 
control groups (case-control analysis). Association analysis can be utilized in both 
family and population samples. The detected association can then be direct or 
indirect, LD-based. Moreover, natural selection, where a certain allele of a marker is 
favored in the population, population stratification, and false-positive findings can 
cause the allele frequencies to differ between the cases and the controls, and should 
be taken into account as possible causes for association.  
Advantages of candidate gene study are customized selection of markers and lower 
genotyping costs compared with linkage studies based on genome scans. Candidate 
gene studies are, however, narrow in perspective, focusing only on the selected genes.  
 
4.2.6. Genome-wide association studies 
Due to completion of the Human Genome Project and developing genotyping 
techniques, larger study samples and wider marker sets are now available for 
analysis. In genome-wide association studies (GWAS), a panel of SNPs across the 
whole genome is selected for genotyping. GWAS covering the whole genome can 
be though of as an alternative to genome scan -based linkage studies. GWAS can, 
however, utilize population data, whereas linkage studies are tied to family samples. 
Several commercial SNP panels exist, covering 100 000 – 1 000 000 SNPs. The 
SNP selection can concentrate on tag-SNPs, coding SNPs, or equal SNP distribution 
across the genome.  
Genome-wide coverage decreases the need for “educated guessing” or the a priori 
hypothesis utilized in candidate gene studies to select the regions genotyped. 
Interestingly, as Hunter and Kraft (2007) point out, the most robust associations 
from the GWAS have been with novel regions, instead of those already reported; 
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even including regions previously thought not to contain any genes at all.  GWAS 
may thus reveal novel candidate genes as well as whole pathways contributing to the 
disease pathophysiology (Drazen and Phimister 2007, Hunter and Kraft 2007). 
Although the genome-wide association studies greatly facilitate the genotyping task, 
they face severe bioinformatic challenges (discussed in section 3.2.9) and require 
multiple rounds of replication (Evans and Cardon 2006). In addition, gaps are likely 
to remain in the coverage, and valuable information may thus be missed. Amos 
(2007) states that key factors to successful GWAS include use of large, 
homogeneous population samples and careful dissection of the phenotype. 
Currently, results from genome-wide association studies related to cardiovascular 
traits are being published at an accelerating pace, almost on a weekly basis during 
the preparation of this thesis. Ozaki et al. (2002) observed an association of 
lymphotoxin - gene with MI, and Samani et al. (2007) reported several 
chromosomal regions associated with CHD. Herbert et al. (2006) discovered a 
common variant associated with obesity, and Hakornarson et al. (2007) noted that 
KIAA0350 gene was associated with type 1 diabetes. 
 
4.2.7. Gene expression studies 
Gene expression studies address the functional role of a variant of interest, typically 
first identified with linkage or association studies. Based on messenger RNA levels, 
expression studies provide first-hand kownledge on the potential pathophysiological 
changes of a variant at a tissue level. Compared with candidate gene studies targeting 
one or a few genes, tailored expression arrays facilitate the analysis of entire pathways 
and address the role of variants studied as a process rather than as separate pieces. 
Disadvantages of expression studies include difficulty in obtaining the target tissues. 
Dissecting specific brain regions in animals, for example, is challenging, not to speak 
of the difficulty of obtaining such tissues from humans. The levels of mRNA may in 
addition not fully correlate with the actual protein levels.  
 
4.2.8. Interaction studies  
Several different genes are likely to contribute to the genetic basis of complex traits. A 
meaningful way to address this complexity therefore is to simultaneously investigate a 
number of putative risk variants and their relations, instead of single genes. 
Epistasis, interaction between two or more genes, has recently been a hot topic in 
genetic studies. Epistasis is one of the factors complicating the study of complex 
traits compared with monogenic diseases; two interacting loci can alter – mask or 
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enhance – each other’s effects, making it difficult to recognize the loci contributing 
to the traits. This complexity substantially increases when hundreds or thousands of 
potentially contributing loci are taken into account.  
Table 7. Advantages and disadvantages of some common gene identification 
methods. Different gene identification strategies address different research goals. 
Genome scan -based linkage studies on family data have been useful in identifying 
genes for monogenic traits. The linked region can then be fine-mapped for variants 
in a candidate gene study. Association studies can utilize both family and population 
data. Genome-wide association studies cover thousands of SNPs across the genome, 
facilitating the genotyping task. Expression studies focus on the functionality of the 
variants (modified from Miller et al. 2007). 
STUDY TYPE ADVANTAGES DISADVANTAGES 
Linkage study in families Information genome-wide   Requires family samples: problematic in 
very rare diseases 
 Identifies large-scale genetic effects Low resolution: fine-mapping needed 
  Limited power in complex traits 
Association study in 
population-based samples 
More robust in complex traits than 
linkage studies 
Requires large samples to detect small 
effects 
 High resolution Requires replication samples 
 Suitable for both population and family 
samples 
 
Candidate gene study Customized SNP selection Analysis of the selected gene(s) only 
 Lower costs compared with genome-
wide studies 
 
Genome-wide association  Information genome-wide Statistical challenges 
study Detection of small genetic effects Questionable overage 
 Effective genotyping Genotyping costs 
Expression study Functional information at tissue level Difficulty in obtaining target tissues: small 
sample size 
 Analysis of whole pathways: 
customized arrays 
mRNAa and protein levels may not 
correlate 
  Bias due to chip selection 
a mRNA: Messenger RNA 
 
Essentially, epistasis indicates “not independent”. Several definitions and 
interpretations for epistasis do, however, exist. Cordell (2002) reviewed this 
confusing issue. The term epistasis was first introduced by Bateson in 1909 to 
describe a situation where a variant at locus A prevents another variant, B, from 
expressing its effects. The difference between epistasis and traditional models of 
inheritance is the location of the alleles: The epistatic variants are at different sites, 
whereas alleles of the same locus determine dominant and recessive inheritance 
patterns. In 1918, Fisher gave another definition for epistasis as deviation from 
additivity. According to Cordell, Bateson’s definition corresponds closely to 
biological interaction whereas Fisher’s definition is closer to mathematical 
interaction models.  
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Currently, three commonly used interaction models exist to define the outcome, the 
penetrance (pij) of genotype i at locus  and genotype j at locus :  
an additive model (Risch 1990):  
pij = i + j   (I), 
a multiplicative model (Hodge 1981, Risch 1990): 
pij = i j    (II), 
and a heterogeneity model (Risch 1990, Neuman and Rice 1992): 
 pij = i + j - i    (III). 
The multiplicative model can be used when the different contributing loci are not 
considered independent of each other; the additive and heterogeneity models, in 
turn, assume at least some extend of independence in the loci (Cordell 2002).  
The challenge in complex trait studies is to achieve sufficient statistical power to 
detect minor effects in the numerous loci contributing to the disease. The ability to 
detect such minor effects can be enhanced by interaction studies and by selecting a 
suitable model for interaction (Cordell et al. 2001), although one should proceed 
cautiously when drawing biological conclusions from statistical interaction.  
No clear consensus regarding how to address interaction in genetic studies exists 
since the models of inheritance remain mainly unknown. In recent works, the 
multiplicative model has been the dominant choice for interaction, although the 
results have been negative. Weedon et al. (2006) analyzed three common variants 
previously suggested to predispose to T2DM using deviation from the multiplicative 
model as a measure for interaction, but found no evidence of epistasis between the 
loci. Maier et al. (2005) tested several variants of three type 1 diabetes susceptibility 
genes under the multiplicative model, but found no evidence of interaction either. 
Cordell et al. (2001) tested all three common interaction models using two pairs of 
susceptibility loci for type 1 diabetes, and found evidence in favor of the additive 
model, rejecting the multiplicative one.  
Classification trees are one possible approach to study interaction. Classification 
trees attempt to find a variable best predicting a desired disease outcome from a 
dataset, also determining a cut-off point for this variable. The first (best-predicting) 
variable then becomes a root node for a tree-like structure. The data are 
subsequently divided into smaller groups. The branches of trees grow to define 
subgroups holding certain features; in the case of complex traits, mixtures of genetic 
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and environmental risk factors. Classification trees are thus useful in structuring 
noisy datasets with numerous variables, such as genetic data containing several 
SNPs. Gruenewald et al. (2006) used classification trees to identify factors 
contributing to mortality in the elderly and discovered several risk-increasing 
biomarker combinations. Among complex trait genetic studies, Baessler et al. (2007) 
analyzed epistatic effects of several genes in CHD using classification tree analysis 
and found evidence of SNP interactions predisposing to MI.  
Besides gene-gene relations, genes can interact with environmental factors such as 
smoking or nutritional products. Evidence of gene-environment interactions have 
been observed, for example, with interleukin -1 beta gene and fatty acids in 
development of metabolic syndrome (Shen et al. 2007), with tumor necrosis factor 
alpha gene and smoking in asthma (Wu et al. 2007), with thrombomodulin and 
smoking (Li et al. 2002) in CHD, and with epoxide hydrolase gene and smoking in 
coronary atherosclerosis (Wei et al. 2007). 
 
4.2.9. Multiple testing 
Multiple testing is a major challenge in current genetic approaches. Genome-wide 
association studies may comprise over 1 000 000 SNPs, exponentially increasing the 
number of tests compared with candidate gene studies, which include only a few 
variants. Achieving sufficient statistical power in such large-scale studies requires 
extremely large sample sizes; several thousand cases and controls are likely needed 
to identify relatively small genetic effects in complex traits (Amos 2007). 
Traditional corrections for multiple testing directly adjust a stringent p-value based 
on the number of tests performed. With Bonferroni correction, the significance level 
for GWAS with 1 000 000 SNPs can be set to 10-7 (p=0.05/1 000 000). Such 
conventional methods are stated overly conservative, since LD between the nearby 
variants analyzed likely exists (Conneely and Boehnke 2007). The contributions of 
single variants to a common trait are likely to modest, with risk ratios around 1.5 
(Hunter and Kraft 2007), and such low-risk loci may not reach the stringent 
“genome-wide significance” of 10-7. Thus, alternative methods to validate the 
findings of large-scale SNP studies are warranted. 
Replication of the results in several different study samples increases the probability 
of a true association (Hunter and Kraft 2007). Currently, however, extensive 
inconsistency in findings of complex trait studies exists; different studies may 
analyze different variants of the same gene, and even when a certain variant is linked 
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to a disease, the associating alleles may differ (Clarke et al. 2007). Morgan et al. 
(2007) addressed this issue by analyzing 85 variants previously associated with 
acute coronary syndrome, observing a modest association with a single variant. 
Similarly, Shiffman et al. (2006) were able to replicate only 15 of the 172 previously 
CHD-associated variants.  
False-positive findings are likely to exist in the majority of the published studies. 
False discovery rate (FDR) method sets a selected, study sample and analysis group-
specific threshold for statistical significance. Among the findings passing the 
selected FDR limit, a certain number may prove to be false-positive (Benjamini and 
Yekutieli 2005). The FDR limit can, for example, be set to 10%. FDR does not, 
however, identify which of the positive findings are the false ones. Other methods to 
correct multiple testing include permutation, where a sample-specific threshold for 
statistical significance is calculated based on simulations performed (Conneely and 
Boehnke 2007). Functional studies on associated variants also provide evidence of a 
true association.  
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AIMS OF THE STUDY 
The purpose of this thesis work was to investigate the role of five biologically relevant 
candidate genes in cardiovascular diseases at the population level using large study 
samples from the Nordic countries. Specific aims of the study were as follows: 
 
• To investigate the role of thrombomodulin variants in coronary 
and ischemic stroke events (I), 
• To investigate the epistatic effects of F5, ICAM1, PROC, and 
THBD in coronary and ischemic stroke events (II), 
• To clarify the role of the allelic variants of USF1 in 
cardiovascular diseases, metabolic syndrome, and its 
component traits (III).  
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MATERIALS AND METHODS 
1. STUDY SAMPLES 
1.1. FINRISK studies 
The FINRISK samples are independent and random population samples collected in 
Finland every five years (www.ktl.fi/finriski). The aim of the FINRISK project is to 
evaluate cardiovascular risk factors at a population level.  
This study utilized two FINRISK samples drawn in 1992 (Vartiainen et al. 1993) 
and 1997 (Vartiainen et al. 1998). The FINRISK-92 sample comprises 5999 
participants from four different geographical regions: Helsinki region, southwestern 
Finland (Turku-Loimaa), North Karelia, and Kuopio region. At baseline, the 
participants were 25-64 years of age. FINRISK-97 contains 8141 participants 
collected from the same four regions and in addition from the province of Oulu. 
These participants were aged 25-74 years at baseline. The participation rate was 
76% in FINRISK-92 and 73% in FINRISK-97. Data on smoking, medication, 
previous CVD events, and family history was collected at baseline with a self-
administrated questionnaire. All participants underwent a physical examination with 
blood pressure and anthropometric measurements. Biological measurements 
performed at baseline include serum lipids (at semi-fasting state) and CRP.   
The FINRISK-92 cohort was followed for 10 years (1992-2001). The follow-up time 
for FINRISK-97 was seven years (1997-2003). Fatal and nonfatal cardiovascular 
events were monitored using the National Causes of Death Register, the National 
Hospital Discharge Register, and specific registers for coronary (FINAMI, Salomaa 
et al. 2003) and stroke events (FINSTROKE, Sivenius et al. 2004). International 
Classification for Diseases (ICD) coding was used to recognize CVD events 
appropriate for the study. ICD-9 codes for fatal coronary events were 410-414 and 
798 and for nonfatal events 410-411, together with ICD-10 codes I20-I25, I46, R96, 
R98, and R99 (fatal CHD) and I20.0, I21, and I22 (nonfatal CHD). For fatal and 
non-fatal ischemic stroke events, ICD-9 codes 433 and 434 (excluding 4330X, 
4331X, 4339X, and 4349X) and ICD-10 code I63 were used. ICD-9 was utilized 
until January 1996 in Finland.  
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1.1.1. Case-cohort study design and genotypic sample 
The FINRISK studies utilize a nested case-cohort study design, where a random 
subsample, a subcohort, is selected from the original study cohort to represent the 
general study population, i.e. the Finns. The case-cohort design differs from the 
classic case-control setting in that the selected subcohort also comprises diseased 
participants – like any normal population.  
Altogether 14 140 people participated in the FINRISK-92 and FINRISK-97 studies. 
The genotypic sample comprised 2222 participants selected with the following 
criteria:  
1) Everyone with first-ever coronary event (n=401) or ischemic stroke (n=149) 
during follow-up and free of CVD at baseline was selected for genotyping 
as incident CVD cases.   
2) Everyone deceased for any reason during follow-up was selected as all-
cause mortality cases (n=610). 
3) Individuals with CVD events at baseline (n=662). 
4) Subcohorts were selected to represent the original study populations 
(n=400, FINRISK-92 and n=386, FINRISK-97).  
 
1.2. ULSAM sample 
The Uppsala Longitudinal Study of Adult Men (ULSAM) is a population cohort 
collected in Uppsala County, Sweden (www.pubcare.uu.se/ULSAM/index). All men 
living in the county, born in 1920-1924, were invited to investigations at four 
different timepoints: at 50, 60, 70, and 77 years of age. All four surveys were 
performed at Uppsala University Hospital.  
The first survey took place in 1970-1973. The response rate was 81.7%; 2322 out of 
the 2841 invited 50-year-old men participated. After 10 years, in 1981-1984, all the 
2130 eligible men aged around 60 years were re-invited to participate. By this time, 
98 had died and 94 were not eligible for other reasons, mainly for having moved out 
of the county. The second survey gathered 1860 participants (87.3% of those 
eligible). The third survey was arranged in 1991-1995, re-inviting all participants of 
the first survey in 1970-1973, including those who did not participate in the second 
survey. The third survey reached 1221 (73%) of the 1681 eligible 70-year-old men. 
 51 
During the 20 years of follow-up, 422 men had died and 219 had moved from 
Uppsala County. In 1997, all 1389 eligible men, now around 77 years of age, were 
once again re-invited to investigations. Altogether 839 men (60%) participated, 
whereas 748 were deceased, and 176 were ineligible for other reasons.    
Each survey contained a self-administrated questionnaire on cardiovascular risk 
factors and medication. Also at each time point, all participants underwent a 
physical examination, including measurements of blood pressure and body 
anthropometric features. Of biological measurements, samples for serum 
cholesterols and fasting glucose were drawn in all four surveys. ApoA-1, ApoB-100, 
and Lp(a) were measured at the first and thrid surveys. Lipid samples drawn in 
1970-1973 were stored in liquid nitrogen until analyzed in 1981 or 1988 (all 
apolipoproteins). The values were adjusted with conversion factors: 1.06 for LDL 
and TC, 0.9 for TG, and 1.17 for HDL, to enable comparison with the Monarch 
method used in the last two surveys. LDL was calculated with Friedewald's formula 
at all ages using 4.0 mmol/l as a cut-off limit for TG. The insulin clamp test was 
performed at the 70 year survey. Table 9 summarizes participant data and 
measurements at different timepoints.  
Table 9. Characteristics of the ULSAM study design and measurements relevant to 
the study III (modified from Auro et al. in press).  
 Survey I 
50 years       
1970-1973     
(n=2322)               
Survey II   
60 years            
1981-1984      
(n=1860)               
Survey III       
70 years     
1991-1995      
(n=1221)               
Survey IV        
  77 years      
1997      
(n=839)                 
End of 
follow-
up 
2002 
CVD events a      14 134 373 518 701 
MetS ATPIII b    452 662 878 969 - 
Total mortality    - 98 442 748 1078 
Ineligible    - 94 219 176 - 
Measurements:   Questionnaire c     Questionnaire c     Questionnaire c       Questionnaire c      
 Cholesterols d       Cholesterols d       Cholesterols d         Cholesterols d        
 Blood pressure      Blood pressure      Blood pressure       Blood pressure       
 Fasting glucose     Fasting glucose     Fasting glucose      Fasting glucose      
 BMI BMI, waist grid    BMI, waist grid      Waist grid              
 ApoA-1, ApoB-
100, Lp(a) e 
IVGTT f                ApoA-1, ApoB-
100, Lp(a) e 
  
 IVGTT f                 Insulin clamp   
   Blood samples 
for DNA 
  
a Coronary event or ischemic stroke during follow-up. Nine persons with baseline CVD (50 years of age) had 
another event during follow-up  b ATP III criteria (male-specific) used. Individuals with missing values 
excluded at each timepoint. c Questionnaire gathered information on CVD risk factors such as family history, 
medication, and smoking  d Cholesterols: Total cholesterol, HDL, TG. LDL calculated from Friedewald’s 
formula  e ApoA-1: Apolipoprotein A-1, ApoB-100: Apolipoprotein B-100, Lp(a): Lipoprotein (a)  f IVGTT: 
Intravenous glucose tolerance test.  
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The cohort was followed for cardiovascular events using the National Causes of 
Death Register and the National Hospital Discharge Register. The follow-up lasted 
32 years, from 1970 until 2002. ICD-9 codes 410-414 and ICD-10 codes I20-I21, 
and I25 were used for coronary events, and ICD-9 codes 433-434 and ICD-10 code 
I63 for ischemic strokes. 
 
2. METHODS 
2.1. DNA extraction 
In the FINRISK study, whole blood samples for DNA extraction were collected at 
baseline, stored at -20C, and extracted with a fenolization method modified from 
Vandenplas et al. (1984). Altogether 100 FINRISK samples had low genomic DNA 
yield. These samples were whole-genome amplified with multiply-primed whole 
circle amplification (Silander et al. 2004) from 10 ng of DNA prior to genotyping.  
In the ULSAM study, whole blood samples for DNA extraction were collected at the 
thrid survey from 1150 participants and extracted with a standard salting-out 
procedure. In addition, DNA from paraffin block samples collected from about 500 
individuals who had died during follow-up was extracted from thin sections of 
paraffin-embedded tissues using proteinase K digestion and QIAamp DNA minikits 
(www.qiagen.com). The majority of the paraffin samples derived from non-tumor 
tissue of cancer patients.  
 
2.2. SNP selection  
To capture the common allelic variance of gene loci, all genes were covered with 
dense SNP maps. SNP selection was based on the SeattleSNPs variation discovery 
resource (SeattleSNPs 2005, http://pga.mbt.washington.edu/) using data for 
European descent. One SNP was selected to represent each haplotype block (bin). 
All blocks were initially covered with tag-SNPs, but when the genotyping of the tag-
SNP was challenging, another SNP from the bin was selected. All blocks with a 
frequency of >10% were covered. With the thrombomodulin gene, additional SNPs 
in the single exon and its near vicinity were also genotyped. The factor V Leiden 
mutation is a rare variant not present in the SeattleSNPs database. The mutation has, 
however, previously shown association with CHD (Ng et al. 2006) and stroke events 
(Lalouschek et al. 2005), and was therefore included based on the literature.  
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Initially, 57 SNPs were selected to cover the five gene loci: 24 SNPs in F5, 7 in 
ICAM1, 7 in PROC, 15 in THBD, and 4 in USF1. LD patterns of the selected SNPs 
were analyzed with Haploview3.2 (Barrett et al. 2005). If two SNPs were in tight 
LD (r2>0.8) with each other, only one was included in the data analyses. In addition, 
all SNPs monomorphic in 370 Finns were excluded. 
 
2.3. SNP genotyping 
SNPs of F5, ICAM1, PROC, and THBD – the SNPs analyzed in the FINRISK 
cohorts – were genotyped with Sequenom MassARRAY (www.sequenom.com) 
with 10 ng of DNA, using hME chemistry. Due to technical difficulties, SNP 
rs3216183 of THBD was genotyped with TaqMan (Roche Molecular Systems, 
www.roche.com).  
Several procedures were performed to assure genotyping quality before analyzing 
the data. All SNPs were first genotyped in 60 Finnish trio families of mother, father, 
and child, and the Mendelian inheritance of each SNP was checked. The FINRISK 
cohorts also contained 2% open duplicates and 5% blinded duplicates, which were 
unknown for the laboratory during genotyping. The error rate for genotyping was 
<1/400 in the FINRISK samples, and the success rate 93% or more for each SNP. 
USF1 gene was genotyped in the ULSAM sample. The 1150 DNA samples extracted 
from whole blood were genotyped using single-base primer extension assay with 
fluorescence polarization detection (Hsu et al. 2001) and PerkinElmer Life Sciences 
reagents (las.perkinelmer.com). The genotyping call rate was 95-99%, with 100% 
reproducibility in 300 genotype comparisons (9%) between independent experiments 
for these samples. Of the 500 paraffin samples, only 158 gave reliable genotyping 
results. The rest of the paraffin samples were excluded from data analyses. 
 
2.4. Haplotype analyses 
THBD haplotypes in the Study I were constructed with PHASE2.1.1 program 
(Stephens and Donelly 2003). Haplotype analyses were excluded from Study II 
because the SNP selection for F5, ICAM1, and PROC was based on haplotype block 
information, and LD between the SNPs within each gene was relatively low. 
Haplotypes for USF1 in the ULSAM sample (Study III) were constructed with both 
PHASE2.1.1 (Stephens and Donnelly 2003) and Haploview3.2 (Barrett et al. 2005). 
The USF1 SNPs were in substantial LD with each other, and the minor alleles of the 
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selected SNPs tagged perfectly the three common haplotypes. Thus, separate 
haplotype analyses were excluded. 
 
2.5. Sequencing 
Despite the selection criterion of allele frequency of >10%, some of the genotyped 
SNPs were very rare in the Finnish population. If the minor allele frequency was 
<5%, the genotypes for all the minor allele homozygotes were assured by 
sequencing. To achieve reliable sequencing results, three samples with the other two 
genotyped classes were also sequenced. Sequencing was performed with ABI 
3730xl DNA analyzer (www.appliedbiosystems.com) and BigDye3.1 sequencing 
chemistry, using 5 ng DNA and utilizing both strands. In addition to the rare SNPs, 
all THBD variants were sequenced in 30 chromosomes. No discrepancies with the 
sequenom data were detected.  
 
2.6. Statistical analyses 
Allele frequency comparisons were performed with 2 test. In Studies I and II 
containing FINRISK data, the allele frequencies were compared between the cases 
(CVD or deceased) and the modified subcohort after excluding CVD cases from the 
subcohort. In the ULSAM sample, CVD and MetS cases were compared with the 
individuals free of these conditions.  
Associations of the SNPs with phenotypic variables, such as cholesterol and glucose 
levels, BMI, waist grid, CRP, and blood pressure, were analyzed with general linear 
model (GLM). In Studies I and II, the model was adjusted for age, sex, and cohort. 
Necessary transformations (logtransformation to achieve normality or rank 
procedure) were performed prior to using GLM.  
 
2.6.1. Time-to-event analyses 
Hazard ratios (HRs) for all separate SNPs were calculated with Cox’s proportional 
hazards model (Studies I-III) (Barlow 1994). HR calculations were contained for 
haplotypes in Study I, and in Study II for SNP pairs. Studies I and II used four 
different endpoints: coronary events, ischemic stroke events, the combination of 
these two (i.e. all CVD events), and total mortality. The model was stratified for 
east-west origin in the studies I and II. Study III used all CVD as an endpoint. In all 
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studies, SNPs were analyzed in univariate and multivariate models, adjusted for 
traditional CVD risk factors.  
 
2.6.2. Classification trees 
Classification tree analysis with combined FINRISK-92 and FINRISK-97 cohorts 
was utilized in Study II. The aim of classification tree analysis was to detect specific 
subgroups, represented by tree branches, holding a substantial CVD risk as well as 
to search for epistatic effects between SNPs from the four different genes. Analysis 
was performed with 20 subsamples, each containing 60% of the whole FINRISK 
data. Separate samples were drawn for men (n=10) and women (n=10).  
Classification tree algorithm AnswerTree3.0 of SPSS (www.spss.com) was used in 
the analyses. AnswerTree searches for the variable best explaining the desired 
endpoint, here all CVD (combination of incident coronary and stroke events).  The 
best variable is selected as a root node for the tree structure, followed with the next 
best splits futher dividing the data into subgroups. Significant splits (n=95 
altogether) from the 20 subsamples were determined with 2 test.  
Next, all significant splits were used as root nodes one at a time. This way “a forest” 
of a total of 95 trees was achieved. The purpose of the forest was to reduce the 
importance of the first split since the significance levels of the splits were relatively 
close to each other, and which of the CVD risk factors is the most important remains 
unknown. All SNPs present in >10% of the sex-specific trees (n=11) were selected 
for further analyses with Cox’s proportional hazards model.  
A separate sensitivity analysis was finally performed to address the SNP selection. 
All 36 SNPs were analyzed in Cox’s proportional hazards model to observe any 
significant findings missed by the 11 SNPs selected with classification trees.  
 
2.6.3. Epistatic effects 
The interaction between gene variants was analyzed in Study II. Classification trees were 
first used to search for epistatic effects in stage 1 of the study. In stage 2, the interaction 
was analyzed with Cox’s proportional hazards model in all SNP pairs of the 11 SNPs 
selected for stage 2 analyses. The interaction was determined as a deviation from the 
multiplicative model (Hodge 1981, Risch 1990). A dominant inheritance model was 
used in SNP pairs to gain power, unless a SNP showed significant results with a 
recessive inheritance model when analyzed as a single variant.  
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2.6.4. Longitudinal analyses 
Longitudinal analysis was utilized in Study III. In the ULSAM data, each of the 
participants had 1-4 longitudinal measurements for the same variables from different 
timepoints during the follow-up. The longitudinal component of the data was 
addressed with longitudinal GLM analysis (PROC MIXED procedure of SAS v.8 
for Windows, www.sas.com). Longitudinal models analyze change in a given 
variable in different subgroups (here, genotype classes) as a function of time. The 
rationale was to detect significant variance between the carriers of different allelic 
variants. For example, a change in cholesterol values measured during the four 
surveys may differ between the genotype classes, i.e. carriers of certain allelic 
variants may be at increased risk for dyslipidemias, and longitudinal measurements 
may detect these trends better than single baseline measurements.  
 
2.6.5. Multiple testing 
Multiple testing was conducted in all three studies. Study I yielded negative results. 
Multiple testing was addressed with the use of two independent study cohorts, 
FINRISK-97 as a replication cohort for FINRISK-92. Due to inconsistent findings in 
the two cohorts, multiple testing was not further addressed in the first study. Study II 
included 36 SNPs in the first stage and 11 SNPs in the second. The selection of the 
11 SNPs based on classification trees substantially reduced the number of tests 
performed in the second stage. Multiple testing in stage 2 was further corrected with 
FDR (Benjamini and Yekutieli 2005), using a 10% cut-off limit, predicting that 10% 
of the results may prove false positive. In addition, all SNPs and SNP pairs were 
analyzed in two independent study cohorts, requiring consistent results from both 
cohorts. In Study III, multiple testing was corrected by calculating an appropriate 
significance level with 1000 permutations. 
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RESULTS AND DISCUSSION 
1.      ASSOCIATION OF ALLELIC VARIANTS OF THROMBOMODULIN 
WITH CVD AT POPULATION LEVEL (Study I) 
Soluble thrombomodulin levels have repeatedly been linked with the risk of CHD 
(Salomaa et al. 1999, Wu et al. 2003). Previous works on the THBD gene have 
concentrated on single SNPs, of which rs1042579 and rs3216183 have shown 
association with MI and ischemic stroke (Ireland et al. 1997, Doggen et al. 1998, 
Wu et al. 2001, Cole et al. 2004, Konstantoulas et al. 2004). Ohlin et al. (2004), in 
contrast, concluded that THBD may not contribute to acute coronary syndrome. A 
gene-environment interaction has also been suggested with the THBD gene variants 
and smoking (Li et al. 2002).  
Studies capturing the complete allelic diversity of any relevant candidate gene had 
not been published when initiating this study. We aimed to fully cover all known 
major variants of the thrombomodulin gene and to address their role in CVD at a 
population level using two independent prospective population cohorts, FINRISK-
92 and FINRISK-97. 
We genotyped 15 SNPs at the thrombomodulin gene locus: 3 SNPs in the promoter 
region, 5 in the single exon of the gene, 4 in the 3’ untranslated region, and 3 in the 
intergenic region downstream from the THBD gene (Figure 7, Table 10). Of the 15 
SNPs, 6 were excluded as monomorphic in the Finnish population, including 4 of 
the exonal SNPs. The fifth coding region SNP (rs1042579) was in perfect LD with 
rs3176123. The rest, 8 SNPs, were selected for data analyses. 
Figure 7. Thrombomodulin gene and the SNP studied (modified from Auro et al. 
2006). 
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Table 10. Minor allele frequencies of the SNPs genotyped at THBD locus (modified 
from Auro et al. 2006).  
 
 
 
 
SNP 
FINRISK-92
Men 
CVD a 
(n=170) 
 
 
Subcohort b 
(n=220) 
 
Women 
CVD a 
(n=86) 
 
 
Subcohort b 
(n=104) 
FINRISK-97
Men 
CVD a 
(n=204) 
 
 
Subcohort b 
(n=231) 
 
Women 
CVD a 
(n=68) 
 
 
Subcohort b 
(n=71) 
1=Rs6113909 0.37          0.38 0.41 0.37 0.44 0.45 0.39 0.39 
2=Rs6082986 0.31          0.28 0.33 0.28 0.36 0.36 0.30 0.31 
3=Rs1962 0.15          0.17 0.14 0.20 0.16 0.17 0.17 0.14 
4=Rs3176123 0.32          0.33 0.33 0.32 0.29 0.25 0.30 0.31 
5=Rs1042580 0.30          0.30 0.32 0.29 0.37 0.36 0.33 0.31 
6=Rs3176122 0 0 0 0 0 0 0 0 
7=Rs3176121 0 0 0 0 0 0 0 0 
8=Rs1800579 0 0 0 0 0 0 0 0 
9=Rs1800578 0 0 0 0 0 0 0 0 
10=Rs1042579 c 0.32          0.33 0.33 0.32 0.29 0.25 0.30 0.31 
11=Rs1800577 0 0 0 0 0 0 0 0 
12=Rs1800576 0 0 0 0 0 0 0 0 
13=Rs3176119 0.06 0.03 0.02 0.03 0.03 0.03 0.04 0.04 
14=Rs3216183 0.19          0.21 0.18 0.21 0.36 0.13 0.18 0.17 
15=Rs6048519 0.43          0.43 0.44 0.46 0.43 0.48 0.45 0.37 
a CVD: Indicent coronary event or incident ischemic stroke  b CVD cases removed from the subcohort    
c Excluded due to perfect LD with rs3176123 
 
During follow-up, 401 incident CHD events and incident 148 ischemic strokes were 
recorded, and 610 participants deceased. Of the participants, 21 had both incident 
coronary and incident ischemic stroke event, and 138 of the 610 deceased also had 
an incident CVD event. Of the subcohort members, 88 had CVD already at the 
baseline and 72 had an incident CVD event during follow-up. (Table 11.) 
 
Table 11. Characteristics of the FINRISK-92 and FINRISK-97 study cohorts: CVD 
events and total mortality at baseline and during follow-up (modified from Auro et 
al. 2007). 
Event   FINRISK-
92 
Men 
All 
(n=2833)    
 
 
 
Subcohor
t 
(n=286)     
 
 
Women 
All 
(n=3166) 
 
 
 
Subcohor
t 
(n=114)     
FINRISK-97 
Men        
All     
(n=4092)       
 
 
 
Subcohort
(n=304)      
 
 
Women 
All 
(n=4049)  
 
 
 
Subcohort 
(n=82) 
Total 
Incident CHD 
event         
143 30 53 4 156 14 49 3 401 
Incident stroke        35 8 33 3 59 10 21 2 148 
All-cause 
mortality          
188 34 94 9 242 35 86 8 610 
Baseline CVD         159 29 63 3 322 50 118 6 662 
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Smoking, diabetes, and hypertension were more frequent among the CVD cases than 
in the subcohort. CVD cases also had higher BMI and CRP values. No major 
differences were seen in the cholesterol values. Table 12 summarizes main 
phenotypic characteristics of the genotypic study samples.  
 
Table 12. Phenotypic characteristics (mean [standard deviation] or %) of the 
FINRISK-92 and FINRISK-97 genotypic samples (modified from Auro et al. 2007). 
 FINRISK-92    FINRISK-97    
 Men 
CVD 
(n=170) a 
 
Subcohort  
(n=220) b 
Women 
CVD 
(n=86) a    
 
Subcohort  
(n=104) b     
Men 
CVD 
(n=204) a 
 
Subcohort  
(n=231) b 
Women 
CVD 
(n=68) a      
 
Subcohort  
(n=71) b 
Hypertension (%) 70.6 54.5 78.8 63.5 75.0 65.4 67.6 74.6 
Smoking (%)         39.4 24.5 16.5 9.6 27.0 23.4 20.6 11.3 
Diabetes (%)          9.4 4.5 15.3 3.8 13.7 5.6 17.6 7.0 
Age (years)            54.2 (7.7) 52.8 (9.1) 54.9 (8.0)   55.9 (6.7) 61.9 (8.7) 59.9 (10.2) 62.8 (7.4)   63.1 (7.6) 
BMI (kg/m2) c        28.6 (3.9)      27.4 (3.9) 29.3 (5.1)   26.9 (4.7)    28.6 (3.5)       27.5 (3.9)     29.3 (4.5)   27.9 (4.4)   
TC (mmol/l) d, g      6.3 (1.1)       5.8 (1.0)     6.1 (1.3)     6.0 (1.0)      5.8 (1.0)         5.7 (1.0)    6.1 (0.9)     6.0 (1.1) 
HDL (mmol/l) e, g   1.2 (0.3)        1.3 (0.4)     1.4 (0.4)     1.6 (0.4 1.2 (0.3)         1.3 (0.3)       1.4 (0.4)     1.5 (0.4) 
CRP (mg/l) f           4.3 (5.5)        2.6 (3.7)     3.6 (4.8)     1.0 (3.9)      2.9 (3.2)         1.9 (2.4)       3.3 (3.9)     2.7 (4.2) 
a CVD: Incident coronary event or ischemic stroke   b CVD cases removed from the subcohorts   c BMI: Body-
mass index   d TC: Total cholesterol   e HDL: high density lipoprotein cholesterol   f CRP: C-reactive protein    
g Individuals with lipid medication removed 
 
Haplotype analyses with PHASE2.1.1 yielded 35 haplotypes; 25 in the FINRISK-92 
cohort and 30 in FINRISKI-97. The majority of the observed haplotypes were rare, 
and only 7 had a frequency of >5%. The haplotype AAGGTG(-TT)G was 
significantly less common among the CVD cases than in the subcohort in the 
FINRISK-92 sample (14.6% vs. 19.9%, p=0.0054). In the FINRISK-97, the same 
haplotype was, however, more common among the CVD cases than in the subcohort 
(15.1% vs. 12.7%). Similar inconsistency was observed with the haplotypes 
AAGTTG(+TT)T and GGGTCG(+TT)T. AAGTTG(+TT)T seemed a risk haplotype 
for CVD in the FINRISK-92 cohort (frequency of 13.2% among the CVD cases vs. 
10.8% in the subcohort, p=0.039), but not in FINRISK-97 (12.2% vs. 12.3%). The 
haplotype GGGTCG(+TT)T was more common among the CVD cases than in the 
subcohort in FINRISK-92 (18.1% vs. 13.1%, p=0.037), but not in FINRISKI-97, 
where it, instead, seemed protective for total mortality (18.9% vs. 12.7%, p=0.0041). 
(Table 13). 
Cox’s proportional hazards model yielded inconsistent results between the 
FINRISK-92 and FINRISK-97 cohorts. Results from the two separate cohorts were 
even opposite to each other. Table 14 illustrates results achieved in time-to-event 
analysis with the haplotype GGGGTCG(+TT)T. SNPs or haplotypes did not 
associate with any of the phenotypic risk factors, either. Gene-environment 
interaction between the THBD variants and smoking was not observed. 
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Table 13. Major (frequency >5%) haplotypes of the 8 SNPs, and the haplotype 
frequencies in the subcohort and among the CVD patients and the deceased ones 
(modified from Auro et al. 2006). 
 
Haplotype a 
FINRISK-92 
Subcohort b 
 
CVD c 
 
Deceased d 
FINRISK-97 
Subcohort b 
 
CVD c 
 
Deceased d 
GGGTCG(+TT)G 16.2 16.9 18.8 19.7 16.1 17.5 
GGGTCG(+TT)T 13.1 18.1 16.7 18.9 16.7 12.7 
AAGTTG(+TT)G 7.3 9.2 8.9 7.5 7.9 7.6 
AAGTTG(+TT)T 10.8 13.2 13.3 12.3 12.2 12.7 
AAGGTG(+TT)G 13.1 14.2 14.7 10.9 12.4 13.9 
AAGGTG(-TT)G 19.9 14.6 13.8 12.7 15.1 14.8 
AAAGTT(+TT)T 12.8 10.6 10.3 11.8 10.7 13.3 
a For SNPs rs6113909, rs6082986, rs1962, rs3176123, rs1042580, rs3176119, rs3216183, and rs6048519;+ 
TT indicates an insertion; -TT, deletion in rs3216183  b full subcohorts used   c CVD at baseline or during 
follow-up   d Deceased during follow-up 
 
 
Table 14. Association of the haplotype GGGTCG(+TT)T with CVD events and total 
mortality in time-to-event analysis. The two study cohorts provided inconsistent 
results (modified from Auro et al. 2006.) 
 
Endpoint 
 FINRISK-92  
HR a                
 
95% CI b 
 
p 
FINRISK-97  
HR a               
 
95% CI b 
 
p 
Incident coronary events Men 1.73 0.97-3.10 0.064 0.86 0.49-1.51 0.603 
 Women 1.61 0.40-6.44 0.502 0.62 0.16-2.43 0.495 
 All 1.79 1.10-2.91 0.018 0.76 0.47-1.23 0.259 
 
Incident ischemic stroke events Men 0.41 0.09-1.86 0.244 1.44 0.67-3.10 0.353 
 Women 1.35 0.32-5.58 0.683 0.36 0.05-2.39 0.290 
 All 0.63 0.27-1.45 0.277 0.95 0.50-1.80 0.878 
 
All incident CVD events c Men 1.45 0.83-2.54 0.197 1.06 0.64-1.73 0.829 
 Women 1.56 0.54-4.52 0.414 0.52 0.15-1.73 0.285 
 All 1.45 0.91-2.23 0.121 0.85 0.55-1.30 0.846 
 
Total mortality Men 1.56 0.96-2.55 0.073 0.57 0.31-0.82 0.006 
 Women 1.75 0.80-3.81 0.167 0.84 0.29-2.45 0.836 
 All 1.57 1.06-2.33 0.024 0.58 0.39-0.87 0.007 
a HR=Hazard ratio   b CI=Confidence interval   c CVD=Coronary events and ischemic strokes combined 
 
 
This study comprised haplotype analyses, in addition to single SNP analyses. 
Haplotypes represent the allele structure in a single DNA strand and determine the 
genetic variance at a locus more precisely than individual SNPs. Haplotype analysis may 
guide us to discover also more rare variants embedded in the background of common 
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haplotypes (Clark 2004), subsequently identified with regional deep sequencing. Joint 
effects of several individual SNPs contributing to haplotypes may also affect important 
genetic structures, for example protein-binding sites (Clark 2004).  
Haplotype estimation in nonrelatives lacking parental information is, however, 
somewhat problematic. Haplotype estimation programs such as Haploview proceed 
well in estimating general haplotype frequencies in a study sample, but to exceed 
this estimation to individual level is uncertain (Clark 2004). In Study I, this was 
assessed with 40 separate PHASE runs. The haplotypes were then cross-checked 
between individual runs. The 7 major haplotypes yielded consistent results. THBD is 
a very small gene with only one exon, and the SNPs analyzed were within 12 kb 
distance. Study I comprised SNPs selected prior to sequence variation resources, 
such as HapMap or SeattleSNPs, and LD structure between individual THBD SNPs 
ranged from r2 0.8 – 0.01. These factors facilitated the haplotype construction at the 
THBD locus.  
The relationships between soluble hemostatic factors and their genetic determinants 
and between genetic variants and CVD are often complex (Lane and Grant 2000, 
Voetsch and Loscalzo 2004). The major weakness of Study I was the lack of soluble 
thrombomodulin measurements, which could have provided additional information 
on the relations of TM, THBD gene variants, and CVD. 
In conclusion, no consistent associations with CHD or stroke events or total 
mortality were observed with any of the SNPs or haplotypes analyzed. Although 
some suggestive associations were seen in the separate study cohorts, these findings 
could not be confirmed in the other study sample. The results from this study 
suggested that thrombomodulin gene variants are not major independent risk factors 
for CVD, at least not in our population sample. We could not replicate previously 
reported associations of the SNPs rs1042579 and rs3216183 with CHD, nor did we 
find evidence of gene-environment interaction between the THBD variants and 
smoking. Association of the THBD gene variants with cardiovascular events has not 
been firmly established in later studies to date. 
 
2.  ANALYZING F5, ICAM1, PROC, AND THBD VARIANTS AND THEIR CO-
EFFECTS AND THE RISK OF CVD (Study II) 
This study aimed to investigate the role of four CVD-related genes – F5, ICAM1, 
PROC, and THBD – in cardiovascular events at a population level. F5, PROC, and 
 62 
THBD are all participants of the clotting cascade, and defects in the genes or in gene 
products predispose to increased clotting.  
The role of the F5 Leiden mutation in venous thrombosis is well-established (Lane 
et al. 2000, Simmonds et al. 2001), but its role in arterial thrombosis is controversial. 
Ye et al. (2006) recently suggested in a large meta-analysis that the variant 
predisposes to coronary events. Besides the Leiden mutation, data on F5 variants 
and arterial thrombosis are scarce. Protein C deficiency in patients with arterial 
thrombosis has been characterized in single case reports (Cakir et al. 2002, Tiong et 
al. 2003), and protein C is suggested to have a neuroprotective function in ischemic 
strokes (reviewed by Griffin et al. 2006). The relation of genetic PROC variants to 
cardiovascular diseases is largely unknown. ICAM1 is involved in leukocyte 
adhesion and migration at the site of atherosclerotic lesions, a crucial step in 
atherosclerosis development (Ross 1999). High soluble ICAM1 concentrations are 
linked to the risk of CHD (Haugt et al. 1996, Hwang et al. 1997, Malik et al. 2001, 
Jenny et al. 2006). Interestingly, Wu et al. (2003) have suggested that the interaction 
of high sICAM1 and low sTM predict CHD risk. High sICAM1 also relates to 
ischemic stroke events (Simundic et al. 2004, Ehrensperger et al. 2005, Blum et al. 
2006, Wang et al. 2006). Elevated ICAM1 expression has been associated with 
atherosclerosis risk (Davies et al. 1993). However, Nuotio et al. (2003) reported a 
negative association of ICAM1 expression in symptomatic carotic stenosis plaques.  
Our aim was to analyze these four genes simultaneously in order to address potential 
epistatic effects between the gene variants. We hypothesized that simultaneous 
analysis would reveal co-effects missed if examining the genes separately. The study 
covered all known common (>10%) variants of the target genes. We started with 53 
SNPs: 24 in F5, 7 in ICAM1, 7 in PROC, and 15 in THBD (discussed in previous 
chapter). Four F5 SNPs (rs3766103, rs2227245, rs6670678, and rs6029), one ICAM1 
SNP (rs5030352), one PROC SNP (rs2069921), and one THBD SNP (rs1042579) 
were excluded based on LD, whereas 11 SNPs (rs9332566, rs9332625, rs9332587, 
rs1046712 of F5, rs5030388 of ICAM1, and rs1800576, rs1800577, rs1800578, 
rs1800579, rs3176122, rs3176121 of THBD) were excluded as monomorphic in 370 
Finns. This yielded 36 SNPs for stage 1 analyses (Tables 15-17). 
The data analyses were performed in three stages, illustrated in Table 15. In stage 1, 
we built a forest of 95 classification trees, using phenotypic risk factors (diabetes 
status, BMI, blood pressure, TC, HDL, TG, WHR, and CRP) and 36 SNPs, and 
selected 12 SNPs present in >10% of the trees. These included 6 F5 SNPs, and 2 
SNPs of ICAM1, PROC, and THBD each. F5 SNPs rs2420369 and rs970741 
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belonged to the same haplotype block in Haploview-analyses; thus the latter was 
excluded, yielding 11 SNPs to be analyzed at stage 2 (Table 17). 
Table 15. Analysis strategy used in Study II. 
1. 53 SNPs of F5, ICAM1, PROC, and THBD 
2. Removal of monomorphic SNPs and SNPs in thight LD: 36 SNPs analyzed 
in stage 1 
3. Stage 1: 11 SNPs selected for stage 2 based on classification trees 
4. Stage 2: Single SNPs and SNP pairs analyzed in Cox’s proportional 
hazards model 
5. Stage 3: Sensitivity analysis for stage 1: All 36 SNPs analyzed in Cox’s 
proportional hazards model 
 
Table 16. Minor allele frequencies of SNPs excluded from stage 2 analyses 
(modified from Auro et al. 2007). 
 
 
 
SNP 
 
 
 
GENE 
FINRISK-
92 
Men 
CVD a 
(n=170) 
 
 
Subcohort 
b 
(n=220) 
 
Women 
CVD a 
(n=86) 
 
 
Subcohort 
b 
(n=104) 
FINRISK-
97 
Men 
CVD a 
(n=204) 
 
 
Subcohort 
b 
(n=231) 
 
Women 
CVD a 
(n=68) 
 
 
Subcohort 
b 
(n=71) 
Rs970741     F5           0.19          0.19 0.13 0.23  0.20 0.20 0.20 0.21 
Rs6013         F5           0.08 0.08 0.09 0.09  0.07 0.09 0.08 0.09 
Rs9332640   F5           0.43 0.46 0.45 0.47  0.47 0.43 0.45 0.49 
Rs6030       F5           0.28          0.27 0.23 0.32 0.28          0.29 0.28 0.31 
Rs9332618 F5           0.17             0.16 0.18 0.19 0.16          0.16 0.22 0.18 
Rs9332695   F5           0.05             0.06 0.05 0.02 0.05          0.03 0.04 0.02 
Rs9332590   F5           0.34          0.34 0.33 0.29 0.34          0.34 0.32 0.26 
Rs6035 F5           0.03          0.03 0.04 0.07 0.06          0.05 0.04 0.05 
Rs9332575 F5           0.14          0.10 0.11 0.08 0.10          0.12 0.15 0.11 
Rs6019 F5           0.02          0.02 0.02 0.04 0.03          0.03 0.04 0.02 
Rs3753305   F5           0.37          0.38 0.33 0.36 0.36          0.37 0.32 0.32 
Rs5030390 ICAM1   0.02          0.04 0.05 0.05 0.04          0.04 0.01 0.04 
Rs281432 ICAM1   0.45 0.42 0.48 0.48 0.44 0.46 0.42 0.49 
Rs3093030   ICAM1   0.41 0.41 0.39 0.40 0.42 0.43 0.43 0.36 
Rs1799810 PROC 0.33 0.35 0.39 0.33 0.35 0.33 0.25 0.35 
Rs2069920 PROC 0.43 0.42 0.43 0.46 0.42 0.42 0.43 0.39 
Rs2069923   PROC 0.03 0.03 0.04 0.03 0.02 0.03 0.01 0.04 
Rs2069928 PROC 0.24 0.21 0.18 0.21 0.24 0.24 0.29 0.25 
Rs6113909   THBD 0.37 0.38 0.41 0.37 0.44 0.45 0.39 0.39 
Rs6082986   THBD 0.31 0.28 0.33 0.28 0.36 0.36 0.30 0.31 
Rs1962 THBD 0.15 0.17 0.14 0.20 0.16 0.17 0.17 0.14 
Rs3176123 THBD 0.32 0.33 0.33 0.32 0.29 0.25 0.30 0.31 
Rs3176119 THBD 0.06 0.03 0.02 0.03 0.03 0.03 0.04 0.04 
Rs3216183 THBD 0.19 0.21 0.18 0.21 0.36 0.13 0.18 0.17 
a CVD: Indicent coronary event or incident ischemic stroke  b CVD cases removed from the subcohort  
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Table 17. Minor allele frequencies of SNPs selected for stage 2 analyses (modified 
from Auro et al. 2007). 
 
 
 
SNP 
 
 
 
GENE 
FINRISK-92 
Men 
CVD a 
(n=170) 
 
 
Subcohort b
(n=220) 
 
Women 
CVD a 
(n=86) 
 
 
Subcohort b
(n=104) 
FINRISK-97
Men 
CVD a 
(n=204) 
 
 
Subcohort b 
(n=231) 
 
Women 
CVD a 
(n=68) 
 
 
Subcohort b 
(n=71) 
 
 
Location 
Rs2420369 F5             0.37       0.38 0.31 0.42 0.41          0.36 0.36 0.42 Intron 
Rs9332591 F5             0.12                  0.13 0.11 0.13 0.10          0.12 0.13 0.17 Intron 
Rs6025 F5             0.03                  0.03 0.03 0.01 0.03          0.01 0.03 0.03 Exon c 
Rs7542281   F5             0.37          0.34 0.36 0.26 0.32          0.35 0.43 0.33 Intron 
Rs2269648   F5             0.24          0.28 0.23 0.30 0.27          0.25 0.24 0.29 Promoter 
Rs5030347 ICAM1      0.23          0.21 0.23 0.16 0.23 0.18 0.24 0.17 Intron 
Rs5030341 ICAM1      0.33 0.33 0.37 0.38 0.30 0.34 0.30 0.37 Intron 
Rs5937   PROC 0.27 0.31 0.31 0.34 0.37 0.35 0.38 0.39 Exon d 
Rs1401296    PROC 0.31 0.28 0.22 0.28 0.36 0.36 0.30 0.31 3’ 
Rs1042580 THBD 0.30 0.30 0.32 0.29 0.37 0.36 0.33 0.31 3’ 
Rs6048519   THBD 0.43 0.43 0.44 0.46 0.43 0.48 0.45 0.37 Promoter 
 
a CVD: Indicent coronary event or incident ischemic stroke  b CVD cases removed from the subcohort  
 
The study revealed several novel CVD-associated gene variants and their pairwise 
combinations (Table 18). The minor allele of F5 rs7542281 was associated with 
increased risk of both coronary and ischemic stroke events in females. The risk of 
incident CHD events was 2.63 (CI 95% 1.38-5.00, p=0.0033), and of all CVD 
events 2.65 (CI 95% 1.50-4.39, p=0.00061). F5 rs2420369 was associated with all 
CVD events in females, the major allele being the risk-increasing allele. Of SNP 
combinations, F5 rs7542281 and THBD rs14012580 jointly contributed to the risk 
of CHD in females (HR 4.45, CI 95% 1.94-10.19, p=0.00042), the minor alleles 
being the risk increasing alleles.  
The minor allele of ICAM1 variant rs5030347 was associated with increased 
mortality risk in men (HR 2.28, CI 95% 1.55-3.36, p=0.000029). In addition, PROC 
rs1401296 was associated with total mortality in men jointly with ICAM1 
rs5030341 (HR 1.63, CI 95% 1.18-2.24, p=0.0028) and with F5 rs2269648 (HR 
1.80, CI 95% 1.19-2.86, p=0.0069). 
The minor allele of PROC rs1401296 showed association with increased risk of 
stroke events in men (HR 2.84, CI 95% 1.32-6.12, p=0.0077). The F5 Leiden 
mutation (rs6025) was also associated with ischemic stroke in men (HR 4.47, CI 
95% 1.63-12.29, p=0.0037), but the variant is very rare (minor allele frequency 
<5%, Table 17), and could only be analyzed in the combined FINRISK sample. 
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With the incident stroke events in females, the high HRs and wide confidence 
intervals of both rs7542281 and rs2269648 likely reflect the insufficient number of 
cases.  
Table 18. SNPs and SNP pairs associated with CVD in Study II with Cox’s 
proportional hazards model adjusted for smoking, BMI, hypertension, total 
cholesterol/HDL ratio, diabetes, and CRP. Only results for the combined sample of 
FINRISK-92 and FINRISK-97 and significant after multiple testing correction with 
FDR (10% limit) shown (modified from Auro et al. 2007). 
Variant    Gene   Inheritance 
model                 
Endpoint 
(sex) 
HR c CI 95% d p 
Rs7542281    F5 Additive a           CHD (F) 2.63 1.38-5.00 0.0033 
Rs7542281 F5 Additive a           Stroke (F) 13.51 2.82-
64.77 
0.0011 
Rs7542281 F5 Additive a           CVD (F) 2.65 1.50-4.39 0.00061 
Rs2420369 F5 Additive b           CVD (F) 1.81 1.21-2.72 0.0040 
Rs2269648 F5 Additive b           Stroke (F) 11.51 2.25-
58.83 
0.0034 
Rs6025 F5 Dominant a         Stroke (M) 4.47 1.63-
12.29 
0.0037 
Rs1401296 PROC Recessive a         Stroke (M) 2.84 1.32-6.12 0.0077 
Rs5030347   ICAM1 Recessive a         Mortality 
(M) 
2.28 1.55-3.36 0.000029 
Rs7542281 x 
Rs1042580       
F5/THBD Recessive 
a/Dominant a       
CHD (F) 4.45 1.94-
10.19 
0.00042 
Rs5030341 x 
Rs1401296      
ICAM1/PROC Dominant 
a/Dominant a       
Mortality 
(M) 
1.63 1.18-2.24 0.0028 
Rs2269648 x 
Rs1401296      
F5/PROC Dominant 
b/Dominant a       
Mortality 
(M) 
1.80 1.18-2.76 0.0069 
a Minor allele is the risk allele    b Major allele is the risk allele   c HR: Hazard ratio   d CI: Confidence interval 
 
Reports on the role of inherited thrombophilias in arterial thrombosis are 
controversial. Linnemann et al. (2007), together with Boekholdt and Kramer (2007), 
concluded that arterial thrombotic events in patients with venous thrombosis are 
rare, suggesting that inherited thrombophilias do not majorly contribute to arterial 
thrombosis. De Moerloose and Boehlen (2007) stated that inherited thrombophilias 
may play a role in arterial thrombosis in specific subgroups, for example in young 
individuals, or after revascularization procedures. Several reports, on the other hand, 
speak for genetic involvement (Lalouschek et al. 2005, de Paula Sabino et al. 2006, 
Eterovic et al. 2007). These reports have, however, mainly concentrated on the 
Leiden mutation and F2 20210GA variant. Our results with F5, PROC, and THBD 
variants speak for the involvement of thrombosis genes in CHD and ischemic stroke 
in the Finnish population.  
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PROC variant rs1401296 was associated with total mortality jointly with ICAM1 
rs5030341 or F5 rs2269648 variant. ICAM1 variants have previously been linked to 
type 1 diabetes (Ma et al. 2006), bronchial asthma (Nejentsev et al. 2003, Li et al. 
2005), celiac disease (Abel et al. 2006), inflammatory bowel diseases (reviewed by 
Papa et al. 2004), and some cancers (Kammerer et al. 2004, Chen et al. 2006, 
Vinceti et al. 2006), and activated protein C is suggested to reduce body organ 
damage by reducing leukocyte and monocyte activity in inflammatory processes 
independent of its thrombotic actitivities (Grey et al. 1994, Mizutani et al. 2000). 
Contribution of F5, ICAM1, and PROC variants to all-cause mortality may also here 
be distinct from atherosclerotic causes.  
Classification trees may help to structure datasets comprising numerous variables. 
The approach may reveal relations between individual variables or groups of 
variables. Gruenewald et al. (2006), for example, used classification trees to 
determine pathways of biomarkers contributing to mortality in the elderly. In genetic 
studies, classification trees can be used in determination of gene-gene and gene-
environment interactions. Besides cancer genetics (Garcia-Closas et al. 2006, Wu et 
al. 2006, Briollais et al. 2007), classification trees are currently not widely utilized in 
complex diseases, although Baessler et al. (2007) recently identified epistatic 
interactions in two genes affecting the susceptibility of MI and CHD using the 
approach.  
In Study II, classification trees were utilized to filter out the most significant variants 
from among many analyzed. The approach failed to identify any direct epistatic 
effects between the SNPs studied, but did reveal a distinct feature; the most 
significant splits in the trees were for the traditional CVD risk factors, such as 
cholesterols and BMI, whereas the SNPs appeared only in the lower tree branches. 
This suggests that the role of genetic variants is most evident in specific subgroups 
determined by the traditional risk factors. The F5 Leiden mutation, for example, has 
previously been associated with CVD risk among young females with unhealthy 
lifestyles (Rosendaal et al. 1997). Classification tree analyses may facilitate the 
recognition of such specific subgroups of individuals holding a substantial disease 
risk.  
To explore the reliability of the classification tree approach, we performed a 
sensitivity analysis for stage 1 to observe if any significant SNPs were left out from 
stage 2 analyses. All 36 SNPs were analyzed in Cox’s proportional hazards model in 
the separate study cohorts. The results indicated that classification trees performed 
well in detecting the significant SNPs. No consistent associations were seen with 
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any of the other SNPs besides the 12 selected ones. Another way to address the 
reliability of this kind of study would be the use of a separate study sample in the 
classification tree selection step (stage 1), performing the stage 2 analyses using 
other study samples. This, however, was beyond our resources. 
Multiple testing is a major issue in large studies comprising numerous gene variants. 
In complex diseases, the risk of each predisposing variant to the trait is likely 
modest (Hunter and Kraft 2007), and a significance threshold required in strict 
multiple correction methods, such as Bonferroni correction, may prove extremely 
challenging. Inheritance model of the variants in complex traits is, in addition, often 
unknown, which also here increased the number of tests, performed using all 
additive, dominant, and recessive models. We corrected multiple testing with a SNP 
selection procedure performed with classification trees (stage 1), and with FDR 
(stage 2). We chose to use a 10% FDR limit, stating that up to 10% of the results 
presented in Table 18 may prove false positives.  
 
Replicating the results in other independent study cohorts and populations decreases 
the chance for false-positive findings. Replication, however, may refer to 
associations seen with the same gene, haplotype, variant, or allele. We chose to use 
the gold standard of replication (Clarke et al. 2007); to state any finding “true”, the 
same allele was required to be associated with the traits in each of the two 
independent study cohorts.  
 
Sample size proved a major limitation of Study II. Reliable interaction studies 
require very large study samples. Here, the total number of incident CVD cases 
(>500) turned out to be insufficient. Especially ischemic stroke events in the sex-
specific analyses were few. To address rare variants, such as the Leiden mutation, 
with recessive inheritance models would require a substantial numbert of cases (Ye 
et al. 2006), beyond the capacity of our study. Further studies on larger cohorts and 
different populations are therefore necessary to confirm our observations. 
 
To conclude, the results from Study II suggest that the F5 gene variants may 
contribute to CHD and ischemic stroke independently or jointly with THBD 
variants. Variants of F5, ICAM1, and PROC may contribute to all-cause mortality, 
either as single variants or through gene-gene interactions.   
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3. ADDRESSING THE ROLE OF USF1 IN CVD AND METABOLIC TRAITS 
(Study III) 
Extensive studies on USF1 have demonstrated the gene’s impact on traditional 
cardiovascular risk factors, such as serum lipid levels, in FCHL families. Pajukanta 
et al. (2004) first reported an association of the gene with FCHL and dyslipidemias. 
Several other studies have subsequently provided supporting results, confirming the 
role of USF1 in dyslipidemias (Coon et al. 2005, Huertas-Vazquez et al. 2005, 
Komulainen et al. 2006, van der Vleuten et al. 2007). However, the majority of these 
works have used family data ascertained for specific endpoints such as FCHL, and 
concentrated on only few SNPs, mainly rs3737787 and rs207365. Thus, the impact 
of the gene on a population level remains largely unknown, and reports covering the 
full allelic variance are scarce. Komulainen et al. (2006) reported an association of 
USF1 variants with CVD and mortality in women. In men, no association with CVD 
at the population level has been published. Reports on USF1 and MetS/T2DM at 
population level have yielded negative results (Gibson et al. 2005, Ng et al. 2005, 
Zeggini et al. 2006).  
Study III aimed to address the role of USF1 in a large population cohort of Swedish 
men, focusing on incident CHD and ischemic stroke events and CVD risk factors, 
including metabolic syndrome. We analyzed four SNPs, covering the allelic 
variance of the gene. Rs3737787 was in perfect LD with rs2073658 (Figure 8), and 
the former was therefore excluded. The minor alleles of the SNPs were observed to 
precisely tag three major haplotypes: Rs2516839 tagged the haplotype CGC, 
rs2073658 the haplotype TAC, and rs2774279 the haplotype CAT, respectively 
(Figure 8).    
Figure 8. USF1 gene, SNPs genotyped, and the major haplotypes. 
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The cohort was followed up for 32 years for CVD events, and the components of 
metabolic syndrome (TC, TG, HDL, BMI, waist, fasting glucose, and blood 
pressure) were measured at four different surveys over 30 years. Individuals free of 
MetS and CVD in all the four surveys served as healthy controls. Table 19 states the 
study design.  
Table 19. Statistical analyses in the study III were performed in four parts. 
1. Allele frequencies of CVD and MetS groups were compared with those of 
healthy controls free of these conditions (2 test). The allele frequencies of 
the cohort were also compared with a group of healthy Swedish blood 
donors (n=98) because the genotypic sample was drawn in the middle of 
the follow-up when about half of the original participants were deceased. 
2. Hazard ratios were calculated with Cox’s proportional hazards model using 
the combination of incident CHD and ischemic stroke as an endpoint. 
3. Longitudinal GLM analysis was performed to observe the influence of the 
USF1 variants with the phenotypic variables. This analysis was done with 
the whole cohort and then in three subgroups: CVD, MetS, and healthy 
controls.  
4. Cross-sectional analysis at the third survey utilized the four different MetS 
definitions. 
 
Table 20 summarizes main phenotypic characteristic of the study cohort. Mean 
blood pressure and fasting glucose values increased by age, whereas TC and LDL 
values declined. This decline was also observed among those participating to all the 
four surveys, suggesting that it was due to environmental factors, rather than 
selective mortality.  
SNP rs2774279 was associated with metabolic syndrome. The frequency of MetS 
was significantly lower in the minor allele carriers of this SNP than in the control 
group, and the trend was present regardless of the MetS definition used, with the 
exception of the EGIR definition. The association was strongest when using the 
ATPIII definition at 70-years only (p<0.001), followed by the IDF definition at 70 
years, and both ATPIII and IDF when all the four surveys were taken into account 
(p<0.01 for all). With the WHO definition at 70 years, a borderline association was 
seen (p<0.05 but failing multiple testing limit). MetS was more common among the 
minor allele carriers of rs2073658 than in the control group with the IDF definition 
in the third survey (p<0.05), suggesting that this variant increases the risk for MetS. 
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Rs2516839 was not associated with MetS. None of the SNPs were associated with 
CVD when comparing the allele frequencies or with Cox’s hazard model. (Table 
21.) 
Table 20. Phenotypic characteristics (mean [standard deviation]) of the ULSAM 
cohort (modified from Auro et al. in press). 
                                               Survey I                     Survey II                       Survey III                     Survey IV 
                                               50 years                      60 years                          70 years                         77 years               
                                              1970-1973                  1981-1984                      1991-1995                     1997                     
  Variable                              (n=2 322)                    (n=1 860)                       (n=1 221)                      (n=839) 
TC (mmol/l) a                        6.87 (1.31)                  6.31 (1.10)                      5.82 (1.00)                    5.48 (0.96) 
LDL (mmol/l) a                     5.26 (1.24)                  4.28 (0.96)                      3.90 (0.89)                    3.56 (0.84) 
HDL (mmol/l) a                    1.36 (0.40)                   1.19 (0.34)                      1.28 (0.35)                    1.32 (0.33) 
TG (mmol/l) a                       1.93 (1.22)                   1.85 (1.01)                      1.45 (0.78)                    1.36 (0.68) 
Fasting glucose (mmol/l) b   4.96 (0.61)                   4.81 (0.58)                      5.63 (0.58)                    5.48 (0.58) 
Blood pressure (mmHg) c    132/83 (17/11)            140/86 (19/9)                  144/82 (17/9)                149/80 (21/10) 
Lp(a) (U/l) a                          245.87 (305.16)           -                                      305.35 (360.37)            - 
ApoA-1 (g/l) a                       1.43 (0.25)                   -                                      1.28 (0.23)                    - 
ApoB-100 (g/l) a                   1.24 (0.28)                   -                                      1.03 (0.23)                    - 
a Individuals with lipid lowering medication removed (n=166)  b Individuals using glucose lowering medication 
removed (n=196)   c Individuals using antihypertensive medication removed (n=466) 
 
Table 21. Allele frequencies among individuals with metabolic syndrome and 
among healthy controls in the ULSAM study cohort (modified from Auro et al. in 
press). 
Polymorphism      Rs2073658    Rs2774279                         Rs2516839 
MetS ATPIII at 70 years (n=384) 0.33                 0.27 d 0.39 
MetS IDF at 70 years (n=435) 0.35 b 0.28 c 0.38 
MetS EGIR at 70 years (n=269) 0.34 0.30 0.36 
MetS WHO at 70 years (n=413) 0.33 0.29 b 0.39 
MetS ATPIII life-long (n=969) a 0.32 0.29 c 0.39 
MetS IDF life-long (n=905) a 0.32 0.29 c 0.39 
Healthy controls (n=998) 0.30 0.33 0.38 
a Life long: Metabolic syndrome diagnosed at one or more surveys 
b p < 0.05 for difference in the minor allele frequencies between the MetS group and the healthy 
controls 
c p < 0.01 
d p < 0.001 
 
To further dissect the putative protective role of rs2774279 and the putative risk-
increasing role of rs2073658, we analyzed the variants with longitudinal GLM in the 
MetS component traits. Minor allele carriers of rs2774279 had lower BMI in the 
whole cohort (p<0.05) and lower fasting glucose concentrations in the CVD group, 
whereas minor allele carriers of rs2073658 had higher ApoB-100 and TC (illustrated 
in Figure 9) in the MetS group (p<0.05). Borderline findings suggest that the minor 
allele carriers of rs2774279 also had higher HDL cholesterol levels (whole cohort, 
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CVD, and MetS groups), lower fasting glucose values (whole cohort), lower BMI 
(CVD group), and smaller waist grid (whole cohort), but these results did not reach 
statistical significance after multiple testing was corrected with permutations. 
Similarly, the minor allele carriers of rs2073658 had higher LDL (Mets group) and 
higher Lp(a) concentrations (CVD and control groups), although the results were 
statistically insignificant after multiple testing corrections. (Table 22.) 
Table 22. Association (p-values) of the USF1 SNPs with longitudinally measured 
cardiovascular risk factors in longitudinal linear analysis (PROC MIXED of SAS v. 8). 
SNPs analyzed modeling dominant inheritance (modified from Auro et al. in press). 
SNP BMI Waist TC d LDL d HDL d ApoA-1 d ApoB-100 d Lp(a) d Fasting 
glucose 
HOMA 
-cell e 
Rs2073658           
All           
MetS a   0.0142 f 0.0242   0.0136 f    
CVD b        0.0232   
Healthy c        0.0277   
Rs2774279           
All 0.0188 f 0.0685   0.0620    0.0397  
MetS a     0.0242      
CVD b 0.0484    0.0611    0.0116 f 0.0532 
Healthy c           
Rs2516839           
All           
MetS a           
CVD b 0.0460          
Healthy c           
a Metabolic syndrome by the ATP III criteria   b CVD: Individuals with cardiovascular event  c Individuals with 
no CVD events or metabolic syndrome 
d Individuals with lipid-lowering medication removed from the analyses.e Fasting insulin / (fasting glucose -
3.5)  f Significant finding  after multiple testing correction as 5th percentile of 1000 permutations 
 
In the cross-sectional GLM analysis of the third survey at 70 years, minor allele 
carriers of rs2774279 had higher HDL and lower Lp(a) values compared with major 
allele homozygotes with all the four MetS definitions. Further, the minor allele 
carriers of rs2774279 had lower BMI, higher HDL, lower fasting glucose, and 
higher mean glucose disposal in the clamp test (p<0.05 for the whole cohort). 
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Figure 9. USF1 influences metabolic syndrome component traits throughout 
adulthood. Minor allele (T) carriers of SNP rs2073658 had significantly higher total 
cholesterol (TC) values (mmol/l) than major allele homozygotes (C) among 
individuals with metabolic syndrome in the ULSAM study cohort. 
 
Which one of the various MetS definitions is the most useful one is not well 
established. ATPIII is suggested to perform better than IDF in predicting future 
CHD overall (Tong et al. 2007) and in patients with diabetes (Marchesini et al. 
2004), whereas the WHO definition may be sensitive in predicting future diabetes in 
patients with MetS (Laaksonen et al. 2002). We determined MetS using four 
different definitions; ATPIII (NCEP 2001) and IDF (Alberti et al. 2006) in all the 
four surveys, and in addition EGIR (Balkau et al. 2002) and WHO (WHO 1999) 
definitions at 70 years. In this study, the overall prevalence of MetS was 41.7% with 
the ATPIII definition, and 39.0% with IDF (Table 23). Of the participants having 
MetS at baseline (determined by ATPIII), 43.1% had a CVD event in the next three 
decades (Table 23). MetS at baseline was thus a major risk factor for future CVD. 
At 70 years, the ATPIII definition had the best overlap with CVD (33.9%, Table 
23).  
Table 23. Metabolic syndrome and cardiovascular events in the study cohort 
(modified from Auro et al. in press). 
Definition MetS (n) CVD and MetS (n) CVD and MetS (%) 
ATPIII (50 years) a 452 195 43.1 
IDF (50 years) b 394 159 40.4 
ATPIII (70 years) a 384 130 33.9 
IDF (70 years) d 435 128 29.4 
EGIR (70 years) c 296 80 29.7 
WHO (70 years) d 413 123 29.8 
ATPIII (life-long) a 969 358 36.9 
IDF (life-long) b 905 30 33.1 
a ATPIII: National Cholesterol Education Program’s Adult treatment panel III   b IDF: International Diabetes 
Federation  c EGIR: European Group for the Study of Metabolic Syndrome  d WHO: World Health 
Organization 
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With longitudinal data, this study provided valuable information of the influence of 
the USF1 variants on CVD risk factors in adulthood. The study sample has, 
however, some downsides. The cohort comprised only men. The drop-out during the 
30 years of follow-up was large, cutting the number of participants from 2322 to 
839. In addition, measurements carried out varied between the individual surveys 
(Table 9), although performed at same hospital. The major weakness was the 
collection of the DNA samples in the third survey instead of the baseline. To assess 
if this late collection caused bias to the genotype frequencies, additional DNA was 
extracted from paraffin blocks from the deceased ones, although these samples are 
also likely biased as collected mainly from cancer patients. No significant 
differences in the allele frequencies were seen between the whole-blood samples, 
paraffin samples, and healthy Swedish blood donors, suggesting that late DNA 
sampling did not cause major bias. The relation of the USF1 gene with mortality 
could not be assessed in this study. 
As a transcription factor, USF1 regulates the function of numerous genes involved 
in body energy and lipid metabolism (Naukkarinen et al. 2005). Although 
associations of the USF1 variants with FCHL and dyslipidemias have been 
replicated in several works, direction of association is less well established. For 
example with rs2073658, the major allele was the risk allele in the most of the 
family studies (Pajukanta et al. 2004, Huertas-Vazquez et al. 2005, van der Vleuten 
et al. 2007), whereas two population studies have reported the minor allele to be the 
risk allele (Komulainen et al. 2006, Zeggini et al. 2006). Our results in this matter 
support the previous population studies.  The inconsistency in the results suggests 
that underlying gene-gene or gene-environment interactions or both modulate the 
effects of USF1 in CVD and dyslipidemias. A thorough understanding of the 
specific role of the USF1 variants in the human pathophysiology may be achieved 
with future functional studies. 
 
To conclude, the results from this study on Swedish men suggested that the USF1 
variants are associated with metabolic syndrome at a population level. The minor 
allele of SNP rs2774279 may prove protective for MetS, whereas the minor allele of 
rs2073658 may increase MetS risk. Analyses with individual MetS component traits 
support these findings. No association was observed between USF1 variants and 
CHD or ischemic stroke events. 
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4. GENERAL DISCUSSION 
Cardiovascular diseases are and continue to be a major cause of death and disability 
worldwide (Murray and Lopez 1997). Despite advances in disease prevention, 
diagnostics, and treatment, coronary heart disease causes annually about 77 000 
hospitalizations in Finland (www.stakes.fi), accompanied by approximately 14 000 
yearly stroke events (www.stakes.fi). Better understanding of the epidemiology of 
cardiovascular diseases is therefore a challenge. Genetic studies on cardiovascular 
traits may reveal novel insights to recognition of individuals in a substantial disease 
risk. Furthermore, CVD disease mechanisms and research methods used in CVD 
genetics may be extended to other common traits. 
Genetic basis of complex diseases is proposed to consist of several common loci 
(Collins et al. 1997). However, each of the predisposing variants likely has only a 
modest effect on the trait (Collins et al. 1997, Hunter and Kraft 2007). An 
alternative view speaks for rare predisposing loci with strong phenotypic effects, 
often seen in Mendelian traits (Wang et al. 2005). The study of cardiovascular traits, 
as well as that of other common traits, has turned out to be a complex story. 
Although several important candidate genes for CVD have been suggested, the 
wider genetic structures of the traits remain unknown. Focusing on few, previously 
reported gene variants, such as APOE epsilons (Eichner 2002) or the PAI1 -675 
4G/5G mutation (Ariyaratnam et al. 2007), has been characteristic for the majority 
of genetic studies on CVD in the past decades. This holds also for the target genes of 
this work, with the F5 Leiden mutation, Lys469Glu of ICAM1, Ala455Val and          
-1208--1209TTins/del of THBD, and rs3737787 and rs2073658 of USF1.  
We are, however, beginning to understand how polygenic diseases should be 
addressed. Targeting on single polymorphisms fails to explore the full-scale 
influence of any candidate gene or locus for a given trait, and studies comprising 
several variants from different genes are needed to structure the complexity of 
common diseases. Some of the key factors facilitating the study of complex traits are 
listed in Table 24. 
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Table 24. Factors to be considered in the study of common diseases to assure 
reliable results. 
 FACTORS FACILITATING GENE IDENTIFICATION IN COMPLEX TRAITS 
Adequate sampling 
 
- Large sample size: sufficient statistical power   in 
order to identify small genetic effects 
 - Reliable diagnostics of the disease outcomes 
 - Use of population isolates: genetic and  
                  environmental similarity 
Replication of findings - Use of several separate study samples  
 - Functional studies 
Simultaneous analysis of several genes  - Interaction studies  
and entire pathways - Genome-wide studies 
 - Expression studies 
Use of multiple study methods   
Addressing multiple testing  
 
In cardiovascular genetics, association of only few candidate genes with CVD has, 
in fact, been firmly established. Of the thrombosis-related variants, the F5 Leiden 
mutation and F2 20210G/A variant have provided consistent results in several 
studies (Ye et al. 2006). Of lipid genes, APOE (Eichner 2002) and ABCA1 (Clee et 
al. 2001, Frikke-Schmidt et al. 2005) seem the most intriguing candidates. Limited 
sample size likely contributes to the inconsistency in the CVD-related findings. 
Large studies comprising several thousand participants or large meta-analyses have 
failed to replicate the majority of previous findings, reported in smaller studies 
(Shiffman et al. 2006, Ye et al. 2006, Morgan et al. 2007). We could not replicate 
associations previously reported with the THBD variants, nor did we find evidence 
of direct involvement of the USF1 gene on CHD and ischemic stroke.  Inadequate 
sample size may also here partly explain the lack of replication. Especially the 
number of ischemic strokes was limited. 
Studies on CVD also suffer from phenotypic variability. “CVD” may, in fact, refer 
to a variety of different endpoints, such as general atherosclerosis, coronary heart 
disease, MI, family history of CHD, ischemic stroke, or all stroke events, or to any 
combination of the former. With thrombomodulin, for example, Wu et al. (2001) 
used general CHD status as an endpoint, whereas Konstatoulas et al. (2004) used 
coronary events, Cole et al. (2004) ischemic stroke events, Ohlin et al. (2004) acute 
coronary syndrome, and Chao et al. (2004) premature MI, to mention few.  
Heterogeneity of the cardiovascular phenotypes might also here partly explain the 
negative results. All the three studies utilized, in addition to all-cause mortality, 
incident coronary and ischemic stroke events and the combination of these two as 
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endpoints. Although CHD and ischemic stroke have several common risk factors, 
the precise risk profiles of the two groups differ. This is likely true also for the 
genetic risk profiles, although some genes, for example APOE (Eichner 2002, 
Humpries and Morgam 2004, Ariyaratnam et al. 2007), have been firmly linked with 
both CHD and ischemic stroke. In addition, selection of the CVD cases in Studies I-
III was based on the National Hospital Discharge Register and the National Causes 
of Death Register. Precise data on the degree of atherosclerosis, based for example 
on autopsy data or coronary angiography, could provide more accurate phenotypes 
and facilitate the future gene hunt in cardiovascular traits.  
Aging contributes to cardiovascular diseases in several ways. Atherosclerosis 
proceeds by age (Lusis 2000), and CVD risk factor burden increases by age 
(Aromaa 1981, Rahkonen et al. 1998, Aromaa 2002, Goldstein et al. 2006, Vasto et 
al. 2007). The genetic risk factors may, however, play a more important role in 
young (<50 years) patients. Age distribution of the FINRISK participants ranged 
from 25 to 75 years at baseline, and may significantly contribute to results presented 
here. Genetic susceptibility for CVD events may also prove partly age-dependent. 
With USF1, a possible age-genotype interaction was recently reported (Reiner et al. 
2007). In Study III, influence of the USF1 variants on CVD risk factors was not age-
dependent. Age-genotype interaction could not be reliably assessed in this study due 
to late DNA sampling. Studies I and II did not address age-genotype interactions, 
either.  
In addition to inadequate sample sizes and phenotypic variability, population 
stratification may increase the risk for negative or false positive findings. Several 
population bottlenecks in the history of Finland have created regional subisolates 
(Pastinen et al. 2001, Service et al. 2006), and stratification may be present between 
such subisolates. For example, differences in the prevalence of coronary heart 
disease exist between East and West Finland (Ylä-Herttuala et al. 1987). The 
FINRISK samples, however, are collected from four to five different geographic 
areas. We also stratified the time-to-event analyses for the geographic area. The 
ULSAM sample comprised men living in the Uppsala County, Sweden, born in 
1920-1924. At the time, the Swedes were likely a very homogeneous population. 
Population stratification is not likely a major issue in these Nordic study cohorts.  
 
Sex-specific differences appear in the prevalence of CHD and ischemic stroke, men 
being at greater risk (Brown et al. 1996, Sacco et al. 1998, Jousilahti et al. 1999, 
Schreiner et al. 2001). The incidence of CVD events increases by age in both 
genders, but based on autopsy data, women are approximately 15 years “behind” 
men in coronary calcification (Hoff et al. 2001), and young women have less 
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atherosclerosis than men at same the age group (McGill et al. 2000). In a Finnish 
study, men were at 3-fold risk for CHD compared with women (Jousilahti et al. 
1999). Differences in risk factors, markedly in HDL cholesterol and smoking, 
explained up to 50% of the sex-specific risk difference (Jousilahti et al. 1999). 
Although partly explained by lifestyle, sex-specific genetic factors are likely to 
contribute. A recent report stated that the heritability of stroke is greater in women 
than in men (Touze and Rothwell 2007). Pan and coworkers (2007) reported that the 
heritability estimates for traits contributing to CVD, such as blood pressure, LDL 
cholesterol, Lp(a), and TG, have sex-specific differences, which may be X-
chromosome-related, whereas Weiss et al. (2006) stated that significant sex-specific 
differences exist in the genetic distribution of blood pressure, cholesterol levels, 
BMI, and insulin.  
 
In Study II, several variants were associated with CHD and ischemic stroke in 
women, whereas in men, the findings concentrated on total mortality. The 
involvement of F5 SNPs other than the Leiden mutation in CVD, or that of F5, 
ICAM1, or PROC variants in mortality, has not been previously reported. Here, the 
Leiden mutation predisposed to ischemic stroke events in men. Lalouschek et al. 
(2005) and Eterovic et al. (2007) have observed this variant to be more common in 
female subjects suffering from ischemic stroke events than in control subjects. The 
number of female stroke cases in our study cohort was limited, and therefore the 
Leiden mutation as a risk factor for stroke in women could not be analyzed reliably. 
With USF1, Pajukanta et al. (2004) showed that the gene was associated with FCHL 
especially in males with high TG levels. Subsequently, Komulainen et al. (2006) 
reported that the USF1 variants were associated with CVD and mortality in women 
but not in men. A USF1 variant was recently observed to influence TG levels and 
BMI in sex-dependent manner, different alleles of the same variant being the risk-
increasing alleles in women and men (Lee et al. 2007). In Study III, the USF1 
variants were associated with metabolic syndrome and lipid profiles in men (the 
study III). The ULSAM study cohort did not include women.   
 
Unraveling the genetic structures underlying complex traits will likely require use of 
several different methods. Genome scan -based family studies may reveal new 
candidate genes and loci, and investigating monogenic, rare disease forms may also 
provide valuable information on the pathophysiology underlying common disease 
forms. Family studies, however, provide information only on the specific families, 
ascertained for a specific trait, and population-based samples are needed to assess 
the role of the variants at a population level. Linkage studies are also relatively 
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insensitive, and other methods are needed to address the putative small-sized effects 
of the numerous contributing loci likely present in polygenic diseases. In addition to 
large-scale association studies, functional data are required to fully evaluate the role 
of associated variants in practice.  
SNPs occur in average once in every 1000 basepairs (Sachidanandam et al. 2001). 
Non-synonymous variants directly influence the amino acid sequence. The majority 
of all SNPs, however, do not have such direct effects. Synonymous and noncoding 
variants may nevertheless have important effects on gene functions (Knight 2003, 
Knight 2005). Polymorphisms in promoter regions may influence gene expression 
by altering the binding of transcription factors. Regulatory polymorphisms can be 
divided into cis-acting, located in the near vicinity of the target gene, and trans-
acting, which act as regulatory elements for other genes located elsewhere (Knight 
2005). The majority of the regulatory variants are likely trans-acting (Brem et al. 
2002, Schadt et al. 2003). Current research of complex traits is, however, 
concentrated on cis-regulatory variants (Knight 2005); recognition of regulatory 
regions located in far distance, possible within other genes, is challenging.  
 
Of the associating SNPs in Study II, the Leiden mutation is the only non-
synonymous variant. THBD SNP rs1042580, jointly contributing to CHD events in 
women with rs7542281, and rs2269648 of F5, associated with all CVD in women, 
are located in the promoter regions. These promoter variants may act as cis-
regulatory elements, affecting the near-by genes, or as trans-regulatory elements, 
affecting some other genes. PROC rs1401296, associated with stroke as a single 
variant and contributing jointly to all-cause mortality with ICAM1 rs5030341 of F5 
rs2269648, locates to 3’ untranslated region of the gene. The other SNPs associated 
with CVD or mortality in Study II are intronic. Of Study III SNPs, rs2774279 is 
located within ARHGAP30, a novel gene neighboring USF1, and rs2073658 is 
located in an intron.  
 
Effects of synonymous variants, appearing in the coding sequence, and promoter 
region variants, putatively altering gene expression, cannot be understood by 
inspecting the sequence. Expression studies providing information of allele-specific 
difference in the expression in a target tissue are needed to address the significance 
of these variants (Wray et al. 2003). Studies on allele-specific expression patterns 
provide evidence of regulatory polymorphisms (Knight 2005). With USF1, allele-
specific difference in the expression of USF1-regulated genes was seen in fat biopsy 
(Naukkarinen et al. 2005). In addition to altered gene expression, noncoding variants 
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may have effects on splicing, and detected associations may prove indirect, linked to 
underlying, unknown variants. Further functional studies are thus needed to gain a 
thorough understanding on the impact of our findings in the pathophysiology of 
cardiovascular traits.  
 
Our results suggest that gene-gene interactions are likely to modify the effects of 
individual genes and single variants. With USF1, evidence of modulatory gene-gene 
interactions accumulates. Putt et al. (2004) observed that the influence of the USF1 
variants on LDL was BMI-dependent, and Komulainen et al. (2006) reported that 
the gene variants influenced CVD risk factors among those with CHD or ischemic 
stroke events, but not in the healthy subcohort. In Study III, the USF1 variants were 
associated with TC and ApoB-100 in individuals diagnosed with MetS, with fasting 
glucose among CVD patients, and with BMI in the whole study cohort. In addition, 
different alleles of the same USF1 variant may predict the risk in FCHL families 
(Pajukanta et al. 2004, Huertas-Vazquez et al. 2005, van der Vleuten et al. 2007) 
than in the general population (Komulainen et al. 2006, Zeggini et al. 2006). 
Together these observations suggest that other genes modify the effects of USF1.      
 
Enviromental factors may modulate the effects of genetic variants. Here, smoking 
was the only environmental component measured. Smoking promotes thrombosis 
(Miller et al. 1998, Fernandez et al. 2002, Pomp et al. 2007), and may enhance the 
effect of inherited thrombophilias (de Moerloose and Boehlen 2007). Substantial 
risk for CHD events has been observed among young female smokers carrying the 
Leiden mutation (Rosendaal et al. 1997). Gene-environment interaction with THBD 
variants and smoking has been proposed previously (Li et al. 2002), but was not 
observed here. Interaction with smoking was not assessed in Studies II or III.  
 
The genes analyzed in this work are linked to central steps of atherosclerosis 
development. ICAM1 is involved in leukocyte adhesion and migration into 
atherosclerotic lesions, a crucial step in atherosclerosis (Ross 1999).  Dyslipidemias 
are central CVD risk factors and key targets of disease prevention and treatment. 
Lipid accumulation is one of the early signs of atherosclerosis (Stary et al. 1992). 
Dyslipidemias, among other factors, initiate endothelial dysfunction, which 
subsequently leads to progression of atherogenesis (Ross 1999, Lusis 2000). As a 
transcription factor, USF1 regulates the function of numerous genes involved in 
body energy and lipid metabolism (Naukkarinen et al. 2005). Association of the 
USF1 variants with FCHL and dyslipidemias has been replicated in several works. 
Thrombosis is a key feature of advanced atherosclerotic lesions giving rise to 
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clinical complications (Stary et al. 1995). Thrombotic lesions may cause partial or 
total occlusions in the vasculature, leading to ischemia. As participants of the 
coagulation cascade, F5, PROC, and THBD genes are tempting candidate genes for 
arterial thrombosis. Defects in their function result to increased blood clotting. 
Figure 10 provides a schematic view of how the five target genes may contribute to 
CVD.  
Figure 10. Role of the five target genes in CVD.  
 
 
The worldwide health burden of cardiovascular diseases is substantial. Better 
understanding of the pathophysiology of CVD-related traits could help to target 
disease prevention and clinical treatment to individuals at an especially high disease 
risk and provide novel pharmaceutical interventions. Although the genetic basis of 
coronary heart disease and ischemic stroke remains unknown, even single genetic 
findings may facilitate the recognition of high-risk subgroups. Further genetic and 
functional studies are, however, needed to determine the specific meaning of our 
findings in the human pathophysiology. 
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Results of Studies I-III can be summarized as follows: 
1) Thrombomodulin gene variants may not be independent cardiovascular risk 
factors, but may contribute to coronary heart disease through gene-gene 
interactions. 
2) Variants of F5, ICAM1, and PROC may influence the risk of CHD, 
ischemic stroke, and total mortality in the Finnish population.   
3) Simultaneous study of numerous variants from different genes to reveal 
epistatic effects may be one step forward in understanding the molecular 
background of complex traits.  
4) USF1 gene variants may have a role in metabolic syndrome and contribute 
to various component traits of MetS in the Swedish population. 
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CONCLUSIONS 
In the course of this study, important advances have taken place in the gene hunt for 
complex traits. Completion of the Human Genome Project handed us the sequence 
of the human genome. Subsequently, public databases like HapMap and 
SeattleSNPs have provided detailed information of variation in the human genome, 
facilitating the genotyping task. Improving techniques have made it possible to 
efficiently address vast number of genetic variants. Yet, we lack deeper 
understanding of the genetic basis of most common traits.  
This study was designed to address the impact of relevant candidate genes on CVD 
risk at the population level. With the wave of genome-wide association studies, the 
information of critical genes for this trait will rapidly increase compared with 
candidate genes studies; GWAS are not influenced by our previous understanding of 
the biochemical background of the trait. Especially studies analyzing epistatic 
effects of more than one gene will be warranted to structure the complexity of 
common diseases. Genome-wide association studies will at least partly meet this 
need by providing data simultaneously from all the genes in the genome. Analysis of 
these very large datasets is somewhat problematic, tackling with issues of 
replication, multiple testing, and inadequate sampling. In addition, meaningful 
selection of SNPs genotyped is an issue under debate. Amos (2007) states that key 
factors for successful genome-wide association studies include use of large 
homogeneous population samples and careful dissection of the phenotype. The 
population isolates – such as the Finns – are thus likely to remain applealing beyond 
the monogenic era and candidate gene studies.  
According to Pollex and Hegele (2007), SNP studies may not, however, sufficiently 
cover the variation in the human genome. Copy number variations (CNVs) are 
intermediate-sized structural variants – insertions and deletions, duplications, and 
inversions – ranging from 1 kb to 5 Mb (Pollex and Hegele 2007). Since up to 5% of 
the human genome is estimated to be structurally variable, CNVs obviously play an 
important role in complex traits: Stranger et al. (2007) compared the expression 
levels of some 14 000 genes in 210 unrelated individuals and observed that of the 
associated genes, 84% were associated with SNPs, 18% with structural variants, and 
1.3% with both. Developing techniques, such as affordable whole-genome 
sequencing, will facilitate the study of CNVs in the future.  
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The goal of medical genetic studies is to lighten the disease burden by improving the 
disease prevention and treatment. On the way to complete understanding of the 
genetic epidemiology of cardiovascular diseases, identifying single risk variants 
helps to target the efforts on those at substantial disease risk.   
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